

TIME	CARDIOVASCULAR						PAIN						DETAILED NEUROLOGIC ASSESSMENT										
	R/L	R/L	R/L	EDEMA			Pain Scale	Location	Inflammation	Severity	Outcome *	Sedation Score	R/L	R/L	Tracks & Pupils	Anterior Fontanel	MOTOR STR	Verbal Response	Eye Opening	Best Motor Response	Coma Scale Total	Consciousness	Numbness/ Tingling
08	L3	31	Pulse UE	Pulse LEDP	Pulse LEPT			W.BL	A	2+	A	F	3	M	*	2	S	R	Uppr	0	3	AR	-
1000	L3	33	33	33	33	WA	A	2+	E	3	IS	*	*			S	L	Lower	3	6	14	AR	-
00	L3	33	33	33	33	WD	A	2+	A	I	M	*	?	?	?	3	3	Uppt	5	3	6	14	AR
04									I	11	M	*				3	3	Lower	5	3	5	12	AR
									I	11	M	*				3	3	Uppt	5	3	5	12	AR
											*					3	3	Lower	5	3	5	12	AR
										*						3	3	Uppt	5	3	5	12	AR
										*						3	3	Lower	5	3	5	12	AR
										*						3	3	Uppt	5	3	5	12	AR
										*						3	3	Lower	5	3	5	12	AR
										*						3	3	Uppt	5	3	5	12	AR
										*						3	3	Lower	5	3	5	12	AR
										*						3	3	Uppt	5	3	5	12	AR
										*						3	3	Lower	5	3	5	12	AR
										*						3	3	Uppt	5	3	5	12	AR
										*						3	3	Lower	5	3	5	12	AR
										*						3	3	Uppt	5	3	5	12	AR
										*						3	3	Lower	5	3	5	12	AR
										*						3	3	Uppt	5	3	5	12	AR
										*						3	3	Lower	5	3	5	12	AR
										*						3	3	Uppt	5	3	5	12	AR
										*						3	3	Lower	5	3	5	12	AR
										*						3	3	Uppt	5	3	5	12	AR
										*						3	3	Lower	5	3	5	12	AR
										*						3	3	Uppt	5	3	5	12	AR
										*						3	3	Lower	5	3	5	12	AR
										*						3	3	Uppt	5	3	5	12	AR
										*						3	3	Lower	5	3	5	12	AR
										*						3	3	Uppt	5	3	5	12	AR
										*						3	3	Lower	5	3	5	12	AR
										*						3	3	Uppt	5	3	5	12	AR
										*						3	3	Lower	5	3	5	12	AR
										*						3	3	Uppt	5	3	5	12	AR
										*						3	3	Lower	5	3	5	12	AR
										*						3	3	Uppt	5	3	5	12	AR
										*						3	3	Lower	5	3	5	12	AR
										*						3	3	Uppt	5	3	5	12	AR
										*						3	3	Lower	5	3	5	12	AR
										*						3	3	Uppt	5	3	5	12	AR
										*						3	3	Lower	5	3	5	12	AR
										*						3	3	Uppt	5	3	5	12	AR
										*						3	3	Lower	5	3	5	12	AR
										*						3	3	Uppt	5	3	5	12	AR
										*						3	3	Lower	5	3	5	12	AR
										*						3	3	Uppt	5	3	5	12	AR
										*						3	3	Lower	5	3	5	12	AR
										*						3	3	Uppt	5	3	5	12	AR
										*						3	3	Lower	5	3	5	12	AR
										*						3	3	Uppt	5	3	5	12	AR
										*						3	3	Lower	5	3	5	12	AR
										*						3	3	Uppt	5	3	5	12	AR
										*						3	3	Lower	5	3	5	12	AR
										*						3	3	Uppt	5	3	5	12	AR
										*						3	3	Lower	5	3	5	12	AR
										*						3	3	Uppt	5	3	5	12	AR
										*						3	3	Lower	5	3	5	12	AR
										*						3	3	Uppt	5	3	5	12	AR
										*						3	3	Lower	5	3	5	12	AR
										*						3	3	Uppt	5	3	5	12	AR
										*						3	3	Lower	5	3	5	12	AR
										*						3	3	Uppt	5	3	5	12	AR
										*						3	3	Lower	5	3	5	12	AR
										*						3	3	Uppt	5	3	5	12	AR
										*						3	3	Lower	5	3	5	12	AR
										*						3	3	Uppt	5	3	5	12	AR
										*						3	3	Lower	5	3	5	12	AR
										*						3	3	Uppt	5	3	5	12	AR
										*						3	3	Lower	5	3	5	12	AR
										*						3	3	Uppt	5	3	5	12	AR
										*						3	3	Lower	5	3	5	12	AR
										*						3	3	Uppt	5	3	5	12	AR
										*						3	3	Lower	5	3	5	12	AR
										*						3	3	Uppt	5	3	5	12	AR
										*						3	3	Lower	5	3	5	12	AR
										*						3	3	Uppt	5	3	5	12	AR
										*						3	3	Lower	5	3	5	12	AR
										*						3	3	Uppt	5	3	5	12	AR
										*						3	3	Lower	5	3	5	12	AR
										*						3	3	Uppt	5	3	5	12	AR
										*						3	3	Lower	5	3	5	12	AR
										*						3	3	Uppt	5	3	5	12	AR
										*						3	3	Lower	5	3	5	12	AR
										*						3	3	Uppt	5	3	5	12	AR
										*						3	3	Lower	5	3	5	12	AR
										*						3	3	Uppt	5	3	5	12	AR
										*						3	3	Lower	5	3	5	12	AR
										*						3	3	Uppt	5	3	5	12	AR
										*						3	3	Lower	5	3	5	12	AR
										*						3	3	Uppt	5	3	5	12	AR
										*						3	3	Lower	5	3	5	12	AR
										*						3	3	Uppt	5	3	5	12	AR
										*						3	3	Lower	5	3	5	12	AR
										*						3	3	Uppt	5	3	5	12	AR
										*						3	3	Lower	5	3	5	12	AR
										*						3	3	Uppt	5	3	5	12	AR
										*						3	3	Lower	5	3	5	12	AR
										*						3	3	Uppt	5	3	5	12	AR

3-10 YEARS - FACES RATING SCALE							
0	1	2	3	4	5		
No Hurt	Hurts Little Bit	Hurts Little More	Hurts Even More	Hurts Whole Lot	Hurts Worst		
10-18 YEARS - NUMERIC SCALE 0-5							
No Pain	0	1	2	3	4	5	Worst Pain
LOCATION							
A	<i>generalized</i>		D				
B	<i>FACIAL</i>		E				
C			F				
INTERVENTION							
E - Epidural (*See MAR)			P - PCA (*See MAR)				
M - MAR (Oral, IM, IV, SQ- See MAR)			*N - Nonpharmacologic Techniques				
*Evaluation - must be documented in Interdisciplinary Progress Notes.							
OUTCOME		SEDATION SCORES					
*See Notes for Duration and Evaluation	1 - Wide Awake 2 - Drowsy (arouses to verbal/tactile stimuli) 3 - Dozing intermittently (arouses to vigorous stimuli) 4 - Awakens when aroused (responsive to painful stimuli) 5 - Unable to arouse (notify physician)						

		NEUROLOGICAL	
PUPIL REACTION		BEST VERBAL RESPONSE	
B - Brisk	N - Non-Reactive	> 5 YEARS	
S - Sluggish	O - Not Observed	5 - Oriented and converses 4 - Disoriented and converses 3 - Inappropriate words 2 - Incomprehensible sounds 1 - No response	
PUPIL SIZE (mm)		2-5 YEARS	
1    3    5    7	5 - Appropriate words and phrases 4 - Inappropriate words 3 - Persistent cries and/or screams 2 - Grunts 1 - No response		
VITALS: BLOOD PRESSURE		0-23 MONTHS	
S - Soft	F - Full	5 - Smiles, coos appropriately 4 - Cries, consolable 3 - Persistent inappropriate crying and/or screaming 2 - Grunts / agitated / restless 1 - No response	
T - Tense	FL - Flat	MOTOR STRENGTH	
D - Depressed		2 - Normal      T - Tremors 1 - Weak           S - Spontaneous 0 - None	
EYE OPENING		BEST MOTOR RESPONSE	
4 - Spontaneous      2 - To pain 3 - To speech           1 - No response		6 - < 1 yr. spontaneous; > 1 obeys 5 - Localizes Pain 4 - Flexion withdrawal 3 - Flexion-abnormal (decorticate rigidity) 2 - Extension (decerebrate rigidity) 1 - No Response	
Glasgow Coma Score		LEVEL OF CONSCIOUSNESS	
* The scale scores responses from 3-15, with the lower numbers indicating a higher degree of neurologic deficit.		PA - Post Anesthesia CS - Conscious Sedation P - Paralyzing Agent A - Analgesia           S - Sedation AL - Alert               AR - Arousable NR - No Response	
NUMBNESS/TINGLING			

Medical City Dallas Hospital

Medical City Dallas . . .  
**WILLIAMS, LABREA**

WILLIAMS, \_\_\_\_\_  
H00707472988 MR#: H000826583 6/2/2002  
DOB: 07/20/94 7/F Sandell,Sharon R.,M.D.

Form #0912130 D  
(Rev. 2/01) Page 7

#### **IV SITE ASSESSMENTS**

- All IV sites are patent without discoloration, irritation, edema or tenderness  
 B - Blood return verified  
 \* - Further documentation required (See Interdisciplinary Notes)

**PATIENT IDENTIFICATION**

Medical City Dallas Hospital  
**WILLIAMS, LABREA**  
H00707472988 MR#: H000826583 6/2/2002  
DOB: 07/20/94 7/F Sandell,Sharon R.,M.D.

METHOD		FORMULA	PLACEMENT CHECK
A - Assisted Feed		F - Formula	V - Verified
N - Nipple		B - Breast Milk	DURATION
B - Breast		1. _____	Number of minutes
G - Gastrostomy		2. _____	TOLERATION
Ng - Naso-gastric			P - Poor
Og - Oral-gastric			F - Fair
S - Self Feed			G - Good

TIME	OUTPUT										TUBES/DRAINS									
	URINE			ULTRA-FILTRATION			GASTRIC			STOOL			BLOOD			CUM			CUM	
	Vol	pH	Gluc	Blood						Emesis					Vol	Cum	Cum	Cum	Cum	Cum
	Cum		SG	Bil	Protein	Quantity				Quantity		Type	Hemocult		Cum	Cum	Cum	Cum	Cum	Cum
0700	150																			
	150																			
0800																				
0900																				
1000																				
1100																				
1200																				
1300	100																			
	100																			
1400																				
1500	150																			
	150																			
1600																				
1700																				
1800																				
1900	50																			
	50																			
2000																				
2100																				
2200																				
2300																				
2400																				
0100																				
0200																				
0300	LCD									S	L									
	LNP																			
0400																				
0500																				
0600	50																			
	50																			
1015																				
1015																				
24 hr TOTAL																				

INTAKE										OUTPUT										BALANCE									
TYPE:	M - Meconium	B - Brown	F - Formed	S - Seedy	T - Transitional	L - Loose	C - Constipated	W - Watery	QUANTITY:	S - Small	M - Moderate	L - Large	C - Copious	PATIENT IDENTIFICATION:															
Form #0912130C (B) Dept. 640, 645 (Rev. 2/01) Page 6 of 10														Medical City Dallas Hospital															
														WILLIAMS, LABREA															
														MR# H000826583 6/2/2002															
														H00707472988 DOB: 07/20/94															
														7/F Sandell, Sharon R., M.D.															

Today's Weight: \_\_\_\_\_

Yesterday's Weight: \_\_\_\_\_

Admit Weight: \_\_\_\_\_

Birth Weight: \_\_\_\_\_

FOC: \_\_\_\_\_

## PREVIOUS 24°

I: \_\_\_\_\_

O: \_\_\_\_\_

Balance: \_\_\_\_\_

Blood Out Total: \_\_\_\_\_

## NUTRITION/METABOLIC PATTERN

## BREAKFAST

Diet clear NPO for \_\_\_\_\_Food Taken Per:  Self  Assist  Fed All  3/4  1/2  1/4  None  RefusedTolerated diet w/o difficulty: .....  Yes  NoSwallow w/o difficult: .....  Yes  NoCalorie Count: .....  Yes  NoSnack:  All  3/4  1/2  1/4  NoneSupplement:  All  3/4  1/2  1/4  None

## LUNCH

Diet clear lig. NPO for \_\_\_\_\_Food Taken Per:  Self  Assist  Fed All  3/4  1/2  1/4  None  RefusedTolerated diet w/o difficulty: .....  Yes  NoSwallow w/o difficult: .....  Yes  NoCalorie Count: .....  Yes  NoSnack:  All  3/4  1/2  1/4  NoneSupplement:  All  3/4  1/2  1/4  None

## DINNER

Diet \_\_\_\_\_

 NPO for \_\_\_\_\_Food Taken Per:  Self  Assist  Fed All  3/4  1/2  1/4  None  RefusedTolerated diet w/o difficulty: .....  Yes  NoSwallow w/o difficult: .....  Yes  NoCalorie Count: .....  Yes  NoSnack:  All  3/4  1/2  1/4  NoneSupplement:  All  3/4  1/2  1/4  None

110

-111-

TIME	INITIALS	TYPE	ELM	PSYCHOS	AL
			Circulation Check	ROM	Skin Care
			Position	Activity	Visitation
08	MK		R	R M	FPC W W
10	MK		R	R M	FPC W W
13	MH		R	M	FAC W W
15	MH		R	M	FAC W W
17	MH		R	M	FAC
20	SD		R	M	FAC
00	SD		R	GP	FPC
04	SD		R	GP	FPC

**ESSENTIAL LINE MGT. (ELM)**

S - Soft N - No No's \* O - Other

**PSYCHOSOCIAL**

POSITIONS	ACTIVITY
R - Right L - Left A - Abdomen M - Head Midline B - Back	BR - Bed rest OF - Off floor S - Sleeping Ch - Chair Cy - Crying I - Restless W/C - Wheelchair
V - Visit H - Held C - Call K - Kangaroo Care FPC - Family involved in Plan of Care PPC - Patient involved in Plan of Care	AA - Ambulate w/assistance UAL - Up ad lib T - Turn TV - Television BRP - Bathroom privileges
Ps - Both parents M - Mother F - Father Ca - Parents called Si - Siblings here GP - Grandparents FP - Foster parents CM - Chaplain / minister V - Volunteer FR - Friends NC - Nurse called parents O - Other	R - Resting P - Playing H - Held
VISITATION	INTERACTION
Ps - Both parents M - Mother F - Father Ca - Parents called Si - Siblings here GP - Grandparents FP - Foster parents CM - Chaplain / minister V - Volunteer FR - Friends NC - Nurse called parents O - Other	W - Within normal limits: communication participation in care and interaction with environment appropriate for age, development, and stage of illness. * - Further documentation required (See Interdisciplinary Notes)
COPIING	INTERACTION

**PATIENT IDENTIFICATION**

Medical City Dallas Hospital  
**WILLIAMS, LABREA**  
 H00707472988 MR#: H000826583 6/2/2002  
 DOB: 07/20/94 7/F Sandell, Sharon R., M.D.

Form #0912  
(Rev. 2/01) Page

<b>FUNCTIONAL INTERVENTIONS AND ASSESSMENTS</b>	
<input type="checkbox"/> PHYSICAL THERAPY	<input type="checkbox"/> OCCUPATIONAL THERAPY
RX TIME _____	RX TIME _____
<input type="checkbox"/> SPEECH THERAPY	RX TIME _____
<input type="checkbox"/> AUDIOLOGY	<input type="checkbox"/> OTHER
RX TIME _____	
Therapeutic Exercises:	
Functional Activity/Gait Training:	
Therapeutic Feeding/Swallowing:	
Language/Cognition:	
Equipment Issued:	
Patient/Family Education:	
Other:	
Assessment/Recommendations:	

111

-112-

CLINICAL SERVICES DAILY COLLABORATION:			RE-PRIORITIZED PROBLEM / NEEDS / GOALS:	
<input checked="" type="checkbox"/> NUR	= Nursing		Date: 6/3/02	Time: 0900
<input type="checkbox"/> RT	= Respiratory Care		1. Pain #2	6.
<input type="checkbox"/> SW/CM	= Social Worker / Case Manager		2. Fever #1	7.
<input type="checkbox"/> PT	= Physical Therapy		3. K/D #3	8.
<input type="checkbox"/> OT	= Occupational Therapy		4. P/S #4	9.
<input type="checkbox"/> ST	= Speech Therapy		5. D/L #5	10.
<input type="checkbox"/> MNT	= Medical Nutrition Therapy		Signature / Title: McKinney	
<input type="checkbox"/> CNS	= Clinical Nurse Specialist			
<input type="checkbox"/> CLS	= Child Life Specialist			
<input type="checkbox"/> Other:				
DATE & TIME	DISCIPLINE	ACTION	SIGNIFICANT FINDINGS	
6/3/02 0905	NUR	D	Report received. Assessment complete & complete precautions. Afebrile at this time. C/o pain from itching so much. Tylenol & Benadryl administered per orders. BBS O/T. Ossat 100%. RA. Entire body covered in red lesions & pustules. Upper half body more severe than lower half. Instructed on trying not to itch lesions. Urine Dipstick obtained SG 1.010, Protein moderate. Team leader notified. IV infusing LR @ 150cc/hr. Will monitor closely. Arceano bath to be done by mom in the next 30 min. Will keep informed. ————— McKinney	
0930	nur	D	T 38.5 AX. Tylenol administered @ 0810. will monitor. ————— McKinney	
0945	nur	D	IV rate ↓ to 100cc/hr due to occlusion. Status will monitor. ————— McKinney	
1030	nur	E	T 37.5 AX. ————— McKinney	
1100	nur	I	Pt C/o pain @ IV site → getting it wet. Repositioned tape, but no relief. ————— McKinney	

ACTION CODES:

D = Data

I = Intervention

E = Evaluation

## PATIENT IDENTIFICATION

Medical City Dallas Hospital  
**WILLIAMS, LABREA**  
 H00707472988 MR# H000826583 6/2/2002  
 DOB: 07/20/94 7/F Sandell, Sharon R., M.D.  
 -11312

DATE & TIME	DISCIPLINE	ACTION	SIGNIFICANT FINDINGS
		cont -	relief obtained. Signs of infiltration begun. IV was removed. → monitoring
6/3/02 1145	NUR D		IV restarted under sterile technique in a 22 gauge needle. → flushing's complication. Pt. tolerated very well. will re-start fluids and monitor. → monitoring
6/3/02 1300	MUR D		Assessment completed. See flow sheet. Pt. awaked + C/o itching. Pt. calling out for grandmother + sibling. Informed pt. that only pt's mother was at bedside. Pt. s entire upper body (from waist up) covered in lesions. Pt's eye closed, but open to verbal stimuli. Pt. up to bathroom in assistance voided 300cc spec gravity 1.005. HR 130s, carotid + pulse ox monitors intact. POC discussed with mother. RArmboard applied. ME Allen
6/3/02 1320	MUR DI		Pt. o/o chills, covered under 2 blankets. Tylenol + Benadryl administered per M.D. order. Educated pt. on importance of not scratching. ME Allen
6/3/02 1715	MUR DT		Temp 39.4°c axillary. Attempted Ibuprofen po; however, pt. refused any po. Ibuprofen given rectally. Dr. Matson in to see pt. HR 130s. ME Allen
6/3/02 1800	MUR E		Pt. continuing to talk + call out for people she knows but are not present in her room.
			Continued

PATIENT IDENTIFICATION

Medical City Dallas Hospital  
**WILLIAMS, LABREA**  
 H00707472988 MR#: H000826583 6/2/2002  
 DOB: 07/20/94 7F Sandell, Sharon R., M.D.

Form #0912150 Dept. 640, 645  
 Rev. 2/01 Page 10 of 10

-114-13

Date: 06/02/02 Time: 0025	MEDICATION ADMINISTRATION RECORD Medical City Dallas Hospital				Page: 1
WILLIAMS, LABREA H00707472988  H.6D H.601D-1 Sandell, Sharon R. M.D.  CHECKED BY: _____	DIAGNOSIS: RASH FEVER WEIGHT: 39.000kg HEIGHT: 0.47 ( 1.0) BSA: 0.17 UNIT #: H000826583 ADMIT DATE: 06/02/02 AGE/SEX: 7/F ALLERGIES: NO KNOWN DRUG ALLERGIES  NOTES:  ADMINISTRATION PERIOD: 06/02/02 (0715) - 06/03/02 (0714)      START/STOP  0715-1514   1515-2314   2315-0714				
***** SCHEDULED MEDS * *****					
NaCl 0.9%  CLINDAMYCIN PHOSPHATE (CLEOCIN PHOSPHATE) RATE: 65 MLS/HR COMMENTS: 12MG/ML (MAX 12MG/ML) VIAL 150MG/ML (NO DILUTION) USE FOR CLEOCIN USE IF PT > 2 YEARS OF AGE	RX #: 06409224  32.5 ML 390 MG IV Q6H*	06/02/02	1200 1100 K	1800 K 1700	0000 SD 0600 SD
NaCl 0.9%  RANITIDINE (ZANTAC VIAL) RATE: 40 MLS/HR COMMENTS: 2.5MG/ML (MAX) ZANTAC 2.5MG/ML ALIQUOT	RX #: 06409955  20 ML 50 MG IV //P// Q8H	06/02/02	1300 K	2100 SD	0500 SD
Aveeno bath					
acyclovir 780mg Q6° IV x 20 doses					

MEDS NOT GIVEN	INJECTION SITES	SIGNATURE	INITIALS	SIGNATURE	INITIALS
1-NPO 2-REFSED 3-N/V 4-DRS ORDRS 5-OTHER	R-RIGHT AB-ABDOMEN L-LEFT U-UPPER D-DELToid M-MIO G-Gluteal T-THIGH			Bonnie L Sally Denish RN	K SD

WILLIAMS, LABREA

7/F

Sandell, Sharon R. M.D.

H.601D-1

Page: 1

-22114

Date: 06/02/02 Time: 0025		MEDICATION ADMINISTRATION RECORD Medical City Dallas Hospital			Page 2
<b>WILLIAMS, LABREA</b> <b>H00707472988</b> H.60 H.601D-1 Sandell, Sharon R., M.D. CHECKED BY:		DIAGNOSIS: RASH FEVER WEIGHT: 39.000kg HEIGHT: 0.4" ( 1.0) BSA: 0.17 ADMIT DATE: 06/02/02 AGE/SEX: 7/F ALLERGIES: NO KNOWN DRUG ALLERGIES  NOTES:			
ADMINISTRATION PERIOD: 06/02/02 (0715) - 06/03/02 (0714)		START/STOP	0715-1514	1515-2314	2315-0714
***** PRN MEDS * *****					
IBUPROFEN TAB(MOTRIN/ADVIL) DOSE: 400 MG ROUTE: ORAL FREQ: PRN Q 6 hours COMMENTS: PRN T > = 101 UNRESPONSIVE TO TYLENOL USE FOR ADVIL/MOTRIN *** PYXIS ITEM ***		RX #: 06409222	06/02/02 07/02/02	2030 SD	0400 SD
ACETAMINOPHEN BTL(TYLENOL DROPS) DOSE: 580MG=5.8ML ROUTE: ORAL FREQ: PRN Q 4 hours COMMENTS: PRN TEMP > 102 OR PAIN USE FOR TYLENOL DROPS (NOT TO EXCEED 65MG/KG/DAY) *** PYXIS ITEM ***		RX #: 06409958	06/02/02 07/02/02	2345 SD	0030
DIPHENHYDRAMINE HCL CAP(BENADRYL CAP) DOSE: 25 MG ROUTE: ORAL FREQ: PRN Q 6 hours COMMENTS: PRN ITCHING (USE FOR BENADRYL) *** PYXIS ITEM ***		RX #: 06409960	06/02/02 07/02/02	0900 K	2030 SD
Benadryl 25mg IV Q 6° prn itching				1500 K	
Dipurine for specific gravity Q6°				1330 K 1530 K	1930 K 0200 voided in bed
Benadryl 25mg IV Q4°					0035 SD 0400 SD

MEDS NOT GIVEN	INJECTION SITES	SIGNATURE	INITIALS	SIGNATURE	INITIALS
1-NPO	R-RIGHT AB-ABDOMEN				
2-REFSED	L-LEFT U-UPPER				
3-N/V	D-DELTOID M-MID				
4-DRS ORDRS	G-GLUTEAL				
5-OTHER	T-THIGH				

WILLIAMS, LABREA

7/F

Sandell, Sharon R., M.D.

H.601D-1

Page: 2

-23-115

Date: 06/02/02  
Time: 0025

MEDICATION ADMINISTRATION RECORD  
Medical City Dallas Hospital

Page: 3

WILLIAMS, LABREA  
H00707472988

H.6D H.601D-1  
Sandell, Sharon R., M.D.

CHECKED BY:

DIAGNOSIS: RASH FEVER  
WEIGHT: 39.000kg HEIGHT: 0.4" ( 1.0 ) BSA. 0.17 UNIT #: H000826583  
ADMIT DATE: 06/02/02 AGE/SEX: 7/F  
ALLERGIES: NO KNOWN DRUG ALLERGIES

**NOTES:**

ADMINISTRATION PERIOD: 06/02/02 (0715) - 06/03/02 (0714) | START/STOP: 0715-1514 | 1515-2314 | 2315-0714

DEXTROSE 5% 1/2 NS 1000 ML  
POTASSIUM ACETATE 20 MEQ  
WILLIAMS, LABREA H00707472988

0400  
SD

MEDS NOT GIVEN	INJECTION SITES	SIGNATURE	INITIALS	SIGNATURE	INITIALS
1-NPO	R-RIGHT				
2-REFSED	L-LEFT				
3-N/V	D-DELTOID				
4-DRS ORDRS	G-GLUTEAL				
5-OTHER	T-THIGH				

WILLIAMS, LABREA

7/F

Sandell, Sharon R., M.D.

H.601D-1

Page: 3

-24-  
116

Date: 06/03/02  
Time: 0000MEDICATION ADMINISTRATION RECORD  
Medical City Dallas Hospital

Page 1

WILLIAMS, LABREA  
H00707472988H.6D H.601D-1  
Sandell, Sharon R., M.D.CHECKED BY: *Sally Denil RN*DIAGNOSIS: RASH FEVER  
WEIGHT: 39.000kg. HEIGHT: 0.4" ( 10 ) BSA: 0.17 UNIT # H000826583  
ADMIT DATE: 06/02/02 AGE/SEX: 7/F  
ALLERGIES: NO KNOWN DRUG ALLERGIES

NOTES:

ADMINISTRATION PERIOD: 06/03/02 (0715) - 06/04/02 (0714)

START/STOP 0715-1514

1515-2314

2315-0714

\*\*\*\*\* SCHEDULED MEDS \* \*\*\*\*\*

NAACL 0.9%	32.5 ML	RX #: 06409224	06/02/02	1200 <i>M/H</i>	<i>1800</i> <i>1930</i> <i>SD</i>	SD 0000 0600 SD
CLINDAMYCIN PHOSPHATE (CLEOCIN PHOSPHATE)	390 MG					
RATE: 65 MLS/HR	IV	Q6H*	07/02/02			
COMMENTS: 12MG/ML (MAX 12MG/ML)						
VIAL 150MG/ML (NO DILUTION)						
USE FOR CLEOCIN						
USE IF PT > 2 YEARS OF AGE						
NAACL 0.9%	20 ML	RX #: 06409955	06/02/02	1300 <i>M/H</i>	<i>2100</i> <i>SD</i>	0500 SD
RANITIDIINE (ZANTAC VIAL)	50 MG					
RATE: 40 MLS/HR	IV	Q8H	07/02/02			
COMMENTS: 2.5MG/ML (MAX)	//P//					
ZANTAC 2.5MG/ML ALIQUOT						
acyclovir 780 mg Q6° IV x 20 doses			1100 <i>M/H</i>	1800 <i>M/H</i>	0000 <i>SD</i>	0600 <i>SD</i>
Dipstick Urine Q6° for S.G. Call MD > 1.015			0800 <i>1.015</i> 1400 <i>M/H</i>	2000 <i>SD</i> 1.015	0330 <i>SD</i> .015	
CYCLOMYDRIL ophthalmic 1gtt each eye repeat in 15 min				<i>1700 M/H</i>		
POLYSPORIN ophthalmic Apply to lesional areas on eyelids & ID					2000 <i>SD</i>	0000 <i>SD</i>

MEDS NOT GIVEN	INJECTION SITES	SIGNATURE	INITIALS	SIGNATURE	INITIALS
1-NPO	R-RIGHT AB-ABDOMEN				
2-REFSED	L-LEFT U-UPPER				
3-N/V	D-DELTOID M-MID				
4-DRS ORDERS	G-GLUTEAL				
5-OTHER	T-THIGH				

WILLIAMS, LABREA

7/F

Sandell, Sharon R., M.D.

H.601D-1

Page. 1

-117

Date: 06/03/02 Time: 0000	MEDICAL ADMINISTRATION Medical City Dallas Hospital	RECORD	Page 2	
WILLIAMS, LABREA H00707472988	DIAGNOSIS: RASH FEVER WEIGHT: 39.000kg HEIGHT: 0.4" ( 1.0) BSA: 0.17 ADMIT DATE: 06/02/02 AGE/SEX: 7/F ALLERGIES: NO KNOWN DRUG ALLERGIES			
H.6D H.601D-1 Sandell, Sharon R., M.D.	NOTES: <i>Sally Denil RN</i>			
CHECKED BY:		ADMINISTRATION PERIOD: 06/03/02 (0715) - 06/04/02 (0714) START/STOP  0715-1514   1515-2314   2315-0714		
***** PRN MEDS * *****				
IBUPROFEN TAB(MOTRIN/ADVIL) DOSE: 400 MG ROUTE: ORAL FREQ:PRN Q 6 hours COMMENTS: PRN T > = 101 UNRESPONSIVE TO TYLENOL USE FOR ADVIL/MOTRIN *** PYXIS ITEM ***		RX #: 06409222 06/02/02 07/02/02	<i>0610 mtk</i> <i>1315 mtk</i>	2330 SD 0500 SD
ACETAMINOPHEN BTL(TYLENOL DROPS) DOSE: 580MG=5.8ML ROUTE: ORAL FREQ:PRN Q 4 hours COMMENTS: PRN TEMP > 102 OR PAIN USE FOR TYLENOL DROPS (NOT TO EXCEED 65MG/KG/DAY) *** PYXIS ITEM ***		RX #: 06409958 06/02/02 07/02/02	<i>0610 mtk</i> <i>1315 mtk</i>	0030 SD
DIPHENHYDRAMINE HCL VIAL(BENADRYL INJ) DOSE: 25 MG ROUTE: IV FREQ:PRN Q 4 hours COMMENTS: USE FOR BENADRYL *** PYXIS ITEM ***		RX #: 06410866 06/03/02 07/03/02	<i>0810 mtk</i> <i>1310 mtk</i>	0330 SD
COLLOIDAL OATMEAL PKT(AVEENO BATH) DOSE: 1 EA ROUTE: TOPICAL FREQ:AS NEEDED,(TIMES UNDEFINED) COMMENTS: USE FOR AVEENO BATH		RX #: 06410867 06/03/02 07/03/02	<i>0830 mtk</i>	
<i>Lacrilube both eyes Q2° if possible</i>			<i>1840 mtk</i> <i>2000 SD</i>	0000 SD
<i>Iuprofen 400mg pr Q6°</i>			<i>1715 mtk</i>	

MEDS NOT GIVEN	INJECTION SITES	SIGNATURE	INITIALS	SIGNATURE	INITIALS
1-NPO	R-RIGHT AB-ABDOMEN				
2-REFSED	L-LEFT U-UPPER				
3-N/V	D-DELTOID M-MID				
4-DRS ORDRS	G-GLUTEAL				
5-OTHER	T-THIGH				

WILLIAMS, LABREA

7/F

Sandell, Sharon R., M.D.

H.601D-1

Page: 2

-20-118

209

Date 06/03/02  
Time 0000

MEDICAL RECORD - CATION ADMINISTRATION  
Medical City Dallas Hospital

Page 3

WILLIAMS, LABREA  
H00707472988

H.60 H.601D-1  
Sandell, Sharon R M D

CHECKED BY: \_\_\_\_\_

DIAGNOSIS: RASH FEVER  
WEIGHT: 39.000kg HEIGHT: 0.4" ( 1.0 ) BSA: 0.17 UNIT # H000826583  
ADMIT DATE: 06/02/02 AGE/SEX: 7/F  
ALLERGIES: NO KNOWN DRUG ALLERGIES

## **NOTES :**

ADMINISTRATION PERIOD: 06/03/02 (0715) - 06/04/02 (0714) START/STOP I 0715-1514 | 1515-2314 | 2315-0714

DEXTROSE 5% 1/2 NS 1000 ML  
POTASSIUM ACETATE 20 MEQ  
WILLIAMS, LABREA H00707472988

Solumedrol 20mg IV Q12<sup>h</sup>

2100 SD | 0500 SD

MEDS NOT GIVEN 1-NPO 2-REFSED 3-N/V 4-DRS ORDRS 5-OTHER	INJECTION SITES R-RIGHT      AB-ABDOMEN L-LEFT        U-UPPER D-DETOID     M-MID G-GLUTEAL T-THIGH	SIGNATURE	INITIALS	SIGNATURE	INITIALS

WILLIAMS, LABREA

71F

Sandell, Sharon R., M.D.

H 601D-1

Page: 3

-21-

210

Date: 06/04/02 Time 0000	MEDICATION ADMINISTRATION RECORD Medical City Dallas Hospital				Page 1
WILLIAMS, LABREA H00707472988	DIAGNOSIS: RASH FEVER WEIGHT: 39.000kg HEIGHT: 0 4' ( 1.0 ) BSA: 0.17 UNIT #: H000826583 ADMIT DATE: 06/02/02 AGE/SEX: 7/F ALLERGIES: NO KNOWN DRUG ALLERGIES				
H.60 H.601D-1 Sandell, Sharon R., M.D.	NOTES:  CHECKED BY: <i>Sandell RN</i>				
ADMINISTRATION PERIOD: 06/04/02 (0715) - 06/05/02 (0714)		START/STOP	0715-1514	1515-2314	2315-0714
***** SCHEDULED MEDS * *****					
✓ NACL 0.9% CLINDAMYCIN PHOSPHATE (CLEOCIN PHOSPHATE) RATE: 65 MLS/HR COMMENTS: 12MG/ML (MAX 12MG/ML) VIAL 150MG/ML (NO DILUTION) USE FOR CLEOCIN USE IF PT > 2 YEARS OF AGE	RX #: 06409224 32.5 ML 390 MG Q6H*	06/02/02	1200 1400 <i>M/H</i> 1900	1800 1900	0000 0600
✓ NACL 0.9% RANITIDINE (ZANTAC VIAL) RATE: 40 MLS/HR COMMENTS: 2.5MG/ML (MAX) //P// ZANTAC 2.5MG/ML ALIQUOT	RX #: 06409955 20 ML 50 MG IV Q8H	07/02/02	1300	2100 1800 <i>KW</i>	0500
✓ NS 100ML BAG ACYCLOVIR SODIUM (ZOVIRAX) RATE: 112 MLS/HR COMMENTS: USE FOR ZOVIRAX; PREP DATE/TIME **DO NOT REFRIGERATE** STABLE 24 HR POST PREP: MAX CONC = 7mg/ml #VERIFY ORDER PRIOR TO ADMX##	RX #: 06410997 112 ML 780 MG IV Q6H	06/03/02	1200 <i>X20 doses</i> 1400	1800	0000 0600
✓ BACITRACIN/POLYMYXIN B SULFATE TUBE(POLYSPORIN EYE OINTMENT) DOSE:--> APPLY TO LESIONAL AREAS ON EYELIDS ROUTE: OPHTH FREQ: QID @ 08,12,16,20 COMMENTS: /P/ USE FOR POLYSPORIN OPHTH OINT	RX #: 06413858 06/03/02	0800 <i>M/H</i> 1200 <i>M/H</i>	1600 <i>M/H</i> 2000		
✓ LANOLIN/MINERAL OIL/PETROLATUM UD(LACRI-LUBE S.O.P. OINTMENT) DOSE:--> APPLY TO BOTH EYES ROUTE: OPHTH FREQ: Q2H COMMENTS: USE FOR LACRI-LUBE APPLY TO BOTH EYES Q 2 HOURS IF POSSIBLE *** PYXIS ITEM ***	RX #: 06413859 06/03/02	0800 <i>M/H</i> 1000 <i>M/H</i> 1200 <i>M/H</i> 1400	1600 <i>M/H</i> 1800 2000 2200	0000 0200 0400 0600	
MEDS NOT GIVEN 1-NPO 2-REFSED 3-N/V 4-DRS ORDERS 5-OTHER	INJECTION SITES R-RIGHT AB-ABDOMEN L-LEFT U-UPPER D-DELToid M-MID G-GLUTEAL T-THIGH	SIGNATURE <i>M. Williams</i> <i>R. Walton, RN</i>	INITIALS <i>M.H.</i> <i>R.W.</i>	SIGNATURE	INITIALS

WILLIAMS, LABREA

7/F

Sandell, Sharon R., M.D.

H.601D-1

Page. 1

-15120

Date: 06/04/02 Time: 0000		MEDICATION ADMINISTRATION Medical City Dallas Hospital		RECORD		Page 2
WILLIAMS, LABREA H00707472988  H.60 H.601D-1 Sandell, Sharon R., M.D.  CHECKED BY: <u>Sally Denil RN</u>		DIAGNOSIS: RASH FEVER WEIGHT: 39.000kg HEIGHT: 0.4" ( 1.0) BSA: 0.17 UNIT #. H000826583 ADMIT DATE: 06/02/02 AGE/SEX: 7/F ALLERGIES: NO KNOWN DRUG ALLERGIES  NOTES.				
ADMINISTRATION PERIOD: 06/04/02 (0715) - 06/05/02 (0714)		START/STOP	0715-1514	1515-2314	2315-0714	
***** SCHEDULED MEDS * *****						
METHYLPREDNISOLONE SOD SUCC VIAL(SOLU-MEDROL) DOSE: 20 MG ROUTE: IV FREQ: Q12H COMMENTS: USE FOR SOLU-MEDROL *** PYXIS ITEM ***		RX #: 06414401	06/03/02 07/03/02	1000 <i>MIX</i>	2200	
<i>DIC</i>						
clean biopsy site QD c tap H <sub>2</sub> O dress c polysporin			1000 <i>MIX</i>			
dipstick urine Q6° call MD > 1.015			0900 <i>MIX</i> 1500 <i>MIX</i>	2100	0300	
NS 400ml IV over 1°				6045 <i>MIX</i>		
DD%W c 100mL NaCl & KCl @ 30cels°				1340 <i>MIX</i>		
Albumin 25%. 37.5gm IV over 1°				1200 <i>MIX</i>		

MEDS NOT GIVEN	INJECTION SITES	SIGNATURE	INITIALS	SIGNATURE	INITIALS
1-NPO	R-RIGHT AB-ABDOMEN	<i>M. Denil RN</i>	<i>MH</i>		
2-REFSED	L-LEFT U-UPPER				
3-N/V	D-DELToid M-MID				
4-DRS ORDRS	G-GLUTEAL				
5-OTHER	T-THIGH				

WILLIAMS, LABREA

7/F

Sandell, Sharon R., M.D.

H.601D-1

Page 2

-121

212

Date 06/04/02 Time: 0000	MEDICATION ADMINISTRATION RECORD Medical City Dallas Hospital			Page 3
WILLIAMS, LABREA H00707472988  H.60 H.601D-1 Sandell, Sharon R., M.D.  CHECKED BY: <i>Sally Denil RN</i>	DIAGNOSIS: RASH FEVER WEIGHT: 39.000kg HEIGHT: 0.4" ( 1.0) BSA: 0.17 UNIT #. H000826583 ADMIT DATE: 06/02/02 AGE/SEX: 7/F ALLERGIES: NO KNOWN DRUG ALLERGIES  NOTES:			
ADMINISTRATION PERIOD: 06/04/02 (0715) - 06/05/02 (0714)		START/STOP	0715-1514   1515-2314	2315-0714
***** PRN MEDS *****				
IBUPROFEN TAB(MOTRIN/ADVIL) DOSE: 400 MG ROUTE: ORAL FREQ:PRN Q 6 hours COMMENTS: PRN T > = 101 UNRESPONSIVE TO TYLENOL · MAY GIVE PER RECTUM USE FOR ADVIL/MOTRIN *** PYXIS ITEM ***	RX #: 06409222	06/02/02 07/02/02	<i>1840kez PD</i>	
ACETAMINOPHEN BTL(TYLENOL DROPS) DOSE: 580MG=5.8ML ROUTE: ORAL FREQ:PRN Q 4 hours COMMENTS: PRN TEMP > 102 OR PAIN USE FOR TYLENOL DROPS (NOT TO EXCEED 65MG/KG/DAY) *** PYXIS ITEM ***	RX #: 06409958	06/02/02 07/02/02		
DIPHENHYDRAMINE HCL VIAL(BENADRYL INJ) DOSE:25 MG ROUTE: IV FREQ:PRN Q 4 hours COMMENTS: USE FOR BENADRYL *** PYXIS ITEM ***	RX #: 06410866	06/03/02 07/03/02	<i>D/C</i>	
COLLOIDAL OATMEAL PKT(AVEENO BATH) DOSE:1 EA ROUTE: TOPICAL FREQ:AS NEEDED,(TIMES UNDEFINED) COMMENTS: USE FOR AVEENO BATH	RX #: 06410867	06/03/02 07/03/02		
NON-FORMULARY EACH(NON FORMULARY DRUG) DOSE: MAGIC THREE MOUTH WASH: DOSE=4 ML ROUTE: MISC FREQ:PRN Q 6 hours COMMENTS: MAALOX:BENADRYL:VISCOUS LIDOCAINE 1:1:1 (SEND 180 ML) DOSE=4 ML **SWISH/SPIT**	RX #: 06413695	06/03/02 07/03/02		
Fentanyl 15-30 mcg IV QT° PRN			110mL 30mcg	2000 30mcg 1520mL 30mcg 1825mL 30mcg

MEDS NOT GIVEN	INJECTION SITES	SIGNATURE	INITIALS	SIGNATURE	INITIALS
1-NPO	R-RIGHT AB-ABDOMEN	<i>M.E.RN</i>	<i>MH</i>	<i>S.Denil RN</i>	<i>SD</i>
2-REFSED	L-LEFT U-UPPER				
3-N/V	D-DELTOID M-MID				
4-DRS ORDERS	G-GLUTEAL				
5-OTHER	T-THIGH				

WILLIAMS, LABREA

7/F

Sandell, Sharon R., M.D.

H.601D-1

Page: 3

-122

MEDS NOT GIVEN	INJECTION SITES	SIGNATURE	INITIALS	SIGNATURE	INITIALS
1-NPO	R-RIGHT AB-ABDOMEN				
2-REFSED	L-LEFT U-UPPER				
3-N/V	D-DELTOID M-MID				
4-DRS ORDRS	G-GLUTEAL				
5-OTHER	T-THIGH				

WILLIAMS, LABREA

7/F

Sandell, Sharon R., M.D.

H.6010-1

Page: 4

-18- 123

**Memorandum of Transfer****Section A (To Be Filled Out by and at Transferring Hospital)**

1. Name of Hospital: <u>HHC at Marderill</u> Address: <u>1101 S Forest Ln</u> Telephone Number: <u>(469) 566-7420</u>	7. Transferring physician's signature or signature of hospital staff acting under physician's orders:  <u>Tonya W. Harkrider</u>
2. Patient Information (if known) Patient's full name: <u>Labrea Williams</u> Address: <u>8231 Manderill Ln #218</u> Dallas, TX 75231 Telephone Number: <u>(214) 360-0131</u> Sex: <input type="checkbox"/> M <input checked="" type="checkbox"/> F Age: <u>31</u> National Origin: <u> </u> Race: <u> </u> Religion: <u>RapFist</u> Physical Handicap: <u> </u>	8. Date: <u>6-4-02</u> Time: <u>1717</u> Telephone Number: <u>(214) 566-1717</u> Address: <u>1101 S Forest Ln</u> <u>Dallas, TX 75230</u>
3. Next of kin information (if known) Next of kin: <u>Lagendra Williams</u> Address: <u>8231 Manderill Ln #209</u> <u>101 S Dallas, TX 75231</u> Telephone Number: <u>(214) 360-0131</u> Next of kin notified? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	9. Accepting hospital secured by transferring hospital Date: <u>6/4/02</u> Time: <u>1717</u> Name of accepting hospital administration person: <u>Kathleen Spears</u>
4. Date of arrival: <u>6-2-02</u> Time: <u>0530</u>	10. Transferring hospital administration signature:  <u>Tonya W. Harkrider</u>
5. Initial contact with receiving hospital: Date: <u>6-4-02</u> Time: <u>1145</u> Name of contact person at receiving hospital: <u>Kathleen Spears</u>	11. Type of vehicle and company used: <u>AMR 214353-7400</u>
6. Accepting physician secured by transferring physician: Date: <u>6-4-02</u> Time: <u>1145</u> Name of accepting physician: <u>Dr. Hackett</u>	12. Type of equipment and/or personnel needed:  <u> </u>
7. Patient transported to: <u>Parkland Memorial Hospital</u> (facility)	13. Attachments X-Ray <input type="checkbox"/> Physician Progress Notes <input checked="" type="checkbox"/> Lab Reports <input checked="" type="checkbox"/> Nurse Progress Notes <input type="checkbox"/> H & P <input checked="" type="checkbox"/> Medication Record <input type="checkbox"/> Other (specify): <u> </u>

**Section B (To Be Filled Out by and at Receiving Hospital)**

1. Name of Hospital Address: <u> </u> Telephone Number: <u> </u>	4. Receiving physician assuming patient responsibility: Date: <u> </u> Time: <u> </u> Receiving Physician's Signature: Address: <u> </u> Telephone Number: <u> </u>
2. Date of arrival: <u> </u> Time: <u> </u>	5. If response to transfer request was delayed beyond thirty (30) minutes, document the reason(s) for the delay, including any time extensions agreed to by transferring hospital. Use additional sheet, if necessary.  <u> </u>
3. Hospital Administration Signature: Date: <u> </u> Title: <u> </u>	

**INSTRUCTIONS:** The transferring hospital completes Section A of this memorandum, sends the original (white) page plus the attachments required by section 11-2.9 of the Hospital Licensing Standards with the patient, and retains the second (yellow) copy. The receiving hospital completes Section B and retains the form. Both the transferring and receiving hospitals must file the memorandum separately from the patient's medical record and in a manner which will facilitate its inspection by the Texas Department of Health.

**Medical City Dallas Hospital**

Memorandum of Transfer

Form # 0919125 Dept. All Nursing (Rev.04/00)

White: Receiving Hospital

**Patient Identification**

Medical City Dallas Hospital  
**WILLIAMS, LABREA**  
H00707472988 MR#: H000826583 6/2/2002  
DOB: 07/20/94 7/F Sandell, Sharon R., M.D.

Yellow: Medical Record

-73 **124**

Patient Name	Medical Record No.	Date	Time
<b>Physician Certification for Transfer</b>			
<p>I, <u>James Hackett</u>, (physician ordering transfer) certify that the medical benefits reasonably expected from the provision of appropriate medical treatment at <u>Northland Behavioral Center</u> (receiving facility) outweigh the risks to the individual's medical condition from effecting this transfer, based upon the information available at the time of transfer.</p>			
<p><b>Summary of Benefits of Transfer</b> <u>care for desuperfication</u>  <u>evaluated to SVS</u></p>			
<p><b>Risks of Transfer</b> <u>auto w/rooftop, lack of direct phys</u></p>			
<p><b>Risks if the Individual is Not Transferred</b> <u>uniquely into shizocystic Cyst</u></p>			
<p>Physician present at time transfer order was given: <u>yes</u> no</p>			
<p>Physician Present <u>James Hackett</u> (physician's signature) Date <u>6-4-02</u> Time <u>1810</u></p>			
<p>Physician Not Present: _____ Date and Time Order Received _____</p>			
<p>Qualified Medical Person (QMP) Receiving Order to Transfer: _____ (print name) _____ (title)</p>			
<p>QMP Signature: <u>Linda Baskin Madnick</u> Date _____ Time _____</p>			
<p>Physician's Signature: <u>James Hackett</u> Date <u>6-4-02</u> Time <u>1810</u></p>			
<b>Patient Consent for Transfer</b>			
<p>I acknowledge that my medical condition has been evaluated and <u>explained to me</u> by the physician or other qualified medical person and/or my attending physician who has recommended that I be transferred to the service of Dr. <u>Hackett</u> at <u>Northland</u>. The potential benefits of such transfer, the potential risks associated with transfer and the probable risks of not being transferred have been explained to me and I fully understand them. With this knowledge and understanding, I agree and consent to be transferred.</p>			
<p>I have been informed of my rights regarding examination, treatment, and transfer.</p>			
<p><u>X Dr Linda Baskin Madnick</u>  Signature of patient or legally responsible individual signing on patient's behalf  <u>Mother</u>  Relationship to patient</p>		<p><u>Linda Baskin Madnick, RN</u>  Witness  <u>6-4-02</u> 18:30  Date and Time</p>	
<p>The above signature includes understanding and agreement to transfer and release of medical records.</p>			

**Patient Transfer Certification**  
**Physician Certification**  
**Patient Consent for Transfer**  
N5402 07/98 (RC# 0258932)

**PATIENT IDENTIFICATION**

Medical City Dallas Hospital  
**WILLIAMS, LABREA**  
H00707472988 MR#: H000826583 6/2/2002  
DOB: 07/20/94 7/F Sandell, Sharon R., M.D.

**CHART**-74 **125**

Receiving Facility Name & Address <b>Parklind Memorial Hospital</b>				Telephone 511-1111 214-1591-8108
Patient Last Name <b>Williams Labrea</b>	First <b>L</b>	Middle <b></b>	Transfer Date <b>6-4-02</b>	Departure Time <b></b>
Accepting Physician in new facility <b>Dr. Hackett</b>	Primary Diagnosis <b>Steven Johnsons</b>		PT aware <b>By Yes <input type="checkbox"/> No <input checked="" type="checkbox"/></b>	Secondary Diagnosis <b></b>
Allergies: Food / Drug / Latex <b></b>				

**Transfer Orders**

Code Status <b>Full</b>	PTOTAST <b></b>
Medications <b>Zantac 50 mg IV q8</b>	Potential for Rehab <input checked="" type="checkbox"/> Good <input type="checkbox"/> Fair <input type="checkbox"/> Poor
<b>Polysoforin ophthalmic to lesions on eye</b>	Estimated Length of Stay
<b>Iacrilube ointment to eyes q2'</b>	D/C Plan / Goals <b>wound care hydration</b>
<b>Fentanyl 15-30 mg IV q1 hr</b>	Nutrition <b>CL</b>
<b>Odall.</b>	Activity <b>C assistance</b>
	Other Treatments (Dressings, Respiratory, Laboratory, etc.) <b>IVF</b>
Mode of Transport <b></b>	

I certify that SNF services are required to be given on an inpatient basis because of the patient's need for skilled nursing care on a continuing basis for the condition(s) for which he/she was receiving inpatient hospital services prior to his/her transfer to the SNF.

Transferring Physician Signature or Designee  
*[Signature]* Date **6-4-02** Time **1810**

Transferring Physician Address and Phone  
**MCN 872-5666 6717**

**Medical Information (Check Attachments)**

- Advance Directive
- Hospital Face Sheet (must attach)
- Psychosocial Assessment
- History and Physical
- Transfer or Discharge Summary (Physician)
- Physician Consults (specify)  
**See folder enclosed**
- Operative Notes (specify)

- Interdisciplinary Progress Notes
- Most Recent Labs/Radiology Reports
- State Required Regulatory Forms
- Other (specify)

**Ambulance Authorization**

I understand that I may use these or any service I desire. I choose to use the services noted below and understand that I am responsible for cost incurred that are not covered by my insurance.

Patient/Parent Signature  
*Kathleen Bonita Marshall bkl/jlz*

Date  
**6/4/02**

Patient ID

**Medical City Dallas  
Hospital**

**Patient Transfer Summary  
Inter Agency Referral**

Medical City Dallas Hospital  
**WILLIAMS, LABREA**  
H00707472988 MR#: H000826583 6/2/2002  
DOB: 07/20/94 7/F Sandell, Sharon R., M.D.  
**[Redacted]**

## **APPENDIX 3**

UNITED STATES DISTRICT COURT  
NORTHERN DISTRICT OF TEXAS  
DALLAS DIVISION

LA SANDRA MADDEN, Individually and  
on Behalf of LABREA WILLIAMS,  
a minor child,

Plaintiff,

vs.

CIVIL ACTION NO. 3:03CV 0167BD

WYETH d/b/a WYETH, INC., f/k/a  
AMERICAN HOME PRODUCTS  
CORPORATION; WYETH CONSUMER  
HEALTHCARE, an unincorporated  
Division of WYETH, f/k/a WHITEHALL-  
ROBINS HEALTHCARE; AND  
WHITEHALL LABORATORIES, INC.,

Defendants.

**DECLARATION OF ROBERT S. STERN, M.D.**

My name is Robert Stern. I am of sound mind and do not suffer from any disability that would prevent me from giving this my declaration. I have never been convicted of a felony or a crime involving moral turpitude. The information contained herein to the extent it discusses the medical records of LaBrea Williams is within my personal knowledge in that it has been derived from my review of the medical records and is true and correct. The remaining information contained herein is within my personal knowledge and is true and correct and based upon my review of the medical records within this case and my knowledge, training and experience.

1. My training, experience, research, and employment are detailed in my Curriculum Vitae, a true and correct copy of which I have attached as Exhibit 1 to this my declaration. Briefly, I graduated from Harvard College (A.B. magna cum laude, Phi Beta Kappa) and Yale Medical School (M.D.). My post graduate training included an internship at Mount Sinai Hospital, New York, a clinical research fellowship in the Epidemiology Branch of the National

Institute of Neurologic Disease and Stroke of the National Institute of Health, a dermatology residency at Harvard Medical School-Massachusetts General Hospital, and a fellowship at the Harvard Center for Community Health and Medical Care. Since 1976 I have been a member of the full time faculty of Harvard Medical School. Currently, I serve as the Carl J. Herzog Professor of Dermatology at Harvard Medical School and the Chief of Dermatology at the Beth Israel Deaconess Medical Center, which is a principle teaching hospital of Harvard Medical School. I am also on the staff of the Brigham and Womens and Childrens Hospital of Boston and the Dana Farber Cancer Institute and Harvard Cancer Center. I am the author of more than 135 peer-reviewed publications and 130 book chapters, editorials and reviews and other medical publications, many of which concern adverse reactions to medications, including articles on this topic in the *New England Journal of Medicine*, *JAMA*, and the *Lancet*. My publications have been cited more than 5000 times in the peer-reviewed literature.

2. Among my other experience and research pertinent to the opinions I provide in this declaration are my developing and serving as principal investigator for a specialty-based system for reporting cutaneous adverse reactions and as one of the founders and senior investigators of the international SJS/TEN study. I have given invited lectures concerning adverse drug reactions on three continents and was invited to provide a staff seminar for the USFDA concerning drug-induced skin eruptions. I have also served as the Chairman for the USP Advisory Panel on Dermatology. I have extensive experience working with the USFDA including more than 10 years as a member of the Dermatologic and Ophthalmic Drug Advisory Committee including a four-year term as Chairman of that committee. Currently, I serve as consultant to the USFDA.

3. With regard to the case of LaBrea Williams, the history taken from the mother, LaSandra Madden, of this seven year-old African American girl revealed that she awoke on the morning of 6/1/02 with multiple facial lesions including blistering lesions of the right cheek. Her other skin lesions included those of the other cheek and forehead. She also had generalized malaise. Before 4:00 p.m., she complained of generalized itching of the skin, which is often a symptom of a generalized skin eruption which is noted before the rash is apparent. She was first treated with Benadryl. After the child's mother took her temperature (104°F) she was given Advil. "At that time the blisters began to appear on the Child's lips." (see Medical City Note 6/2/02 dictation of 5:50 a.m. by Dr. Sandell). The child also reported sore throat and had vomited. When examined between 4:00 a.m. and 5:50 a.m. on 6/2/02, she was noted to have fever, a bullous appearing fluid-filled lesion on her right cheek, multiple small blistering (and swelling) of her lips, multiple papular lesions on a red base of the face, neck, torso, arms, legs, back, (i.e. generalized) as well as erythema of the palms. These areas are reported to be pruritic as was reported prior to 4:00 p.m. on 6/1/04. She also had a red throat. She was admitted to Medical City.

4. Clearly, LaBrea Williams's disease process which included fever, blistering, pruritic rash described before 6:00 a.m. on June 2, 2002, at Medical City represents natural progression of the same disease process reported by the mother prior to 4:00 p.m. on June 1, 2002, when LaBrea first took Advil, which as described by her mother included fever, generalized pruritus (as the first symptom of her not yet apparent generalized red rash), and blistering).

5. By June 2, 2002, the rash was characterized as vesicular and on June 3, 2002, a punch biopsy was performed, which was described as showing "subepidermal vesicle with

superficial perivascular and interstitial dermatitis consistent with erythema multiforme." (Specimen # DL: M02:7498). In the subsequent weeks, LaBrea Williams developed progression of her eruption with increased blistering. Given her fever, blistering rash and mucosal involvement, her condition has features most consistent with both severe Erythema Multiforme Major, Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Although these diseases are rare, in those rare cases that occur in children, cases with features of all three diagnoses are sometimes seen (see Auquier-Durant, *A. Arch Dermatol.* 2002; 138: 1019-1024). Whichever diagnostic term(s) are given in this case with features of both conditions, it is clear that her condition had begun on or prior to awakening on June 1, 2002, which is prior to her first use of Advil. Given that her condition rash, fever, pruritus began before her first use of Advil and for at least two signs/symptoms (rash, pruritus) before her use of Benadryl and the biopsy results and her clinical findings and the absence of any other known exposures to drugs, it is most likely that her condition was an immunologic response to an infectious agent, possibly herpes simplex given her clinical presentation and her paternal grandmother's report that LaBrea had a history of cold sores. Of course, an immunologic reaction to a drug, chemical, environmental agent, or even a food preservative to which LaBrea was exposed prior to the morning of June 1, 2002, cannot be excluded.

6. Simply put, by clinical criteria, by criteria used in credible epidemiologic studies, and by the typical criteria and algorithms used for assessing the cause of severe skin reactions, the onset of LaBrea Williams's febrile mucocutaneous illness was the morning of June 1, 2002, prior to use of ibuprofen (see Roujeau and Stern, Roujeau J C et al *NEJM* 1994 and 1995 respectively). Among the compelling reasons for dating the onset of LaBrea Williams's febrile

mucocutaneous eruption, which eventually evolved into her more generalized blistering eruption are the following:

- 1) she had fever before taking ibuprofen;
- 2) she had skin lesions including blistering lesions of the face before she took ibuprofen;
- 3) she had generalized malaise before taking ibuprofen; and
- 4) and she had generalized itching before taking ibuprofen.

7. Taken together, these four facts and other aspects of her clinical history all indicate that her blistering illness began before she took ibuprofen and was not a result of its use.

8. The signs and symptoms she had before taking ibuprofen are among the most frequent presenting signs and symptoms of erythema multiforme major (EMM), Stevens-Johnson-Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Taken together, the onset of LaBrea Williams's illness was prior to her use of ibuprofen.

9. The initial eruption of EMM/SJS/TEN is often a widespread "morbilliform" eruption exactly as observed in Dr. Sandell's early morning 6/2/02 admitting note, in which she describes an intensely itchy widespread rash of red bumps. In persons with substantial skin pigmentation, the initial pink macular (flat) phase of this eruption is often not observed, particularly in a child with fever where flushing is often observed. However, her pruritus which began before her first use of ibuprofen on 6/2/02 and continued, was like her rash increasing in intensity when her rash was observed early on 6/2/02 to be revised red and bumpy with the careful exam by Dr. Sandell.

10. Even if one accepts the illogical and flawed argument of Plaintiff's experts, that her febrile mucocutaneous blistering disease began early on June 2, 2002 within, at the longest,

14 hours of her first use of ibuprofen, our knowledge of natural history and pathophysiology of drug-induced EMM/SJS/TEN exclude ibuprofen as the cause of LaBrea Williams's illness, with high medical certainty.

11. When due to drugs, chemicals, or other "antigens" such as viruses EMM/SJS/TEN are a result of "delayed" type hypersensitivity reaction which requires "sensitization" before the reaction can be elicited (brought out) by the antigen. Sensitization to a new "antigen" typically requires 5 to 15 days and cannot occur in a matter of hours. In her deposition, LaBrea Williams's mother stated LaBrea Williams had not used ibuprofen before, and one previous medical record three years prior identifies one previous exposure to ibuprofen. Hence, even according to the Plaintiff's experts flawed argument that the patient's illness began early in the morning of 6/2/02, insufficient time had occurred for sensitization to occur and ibuprofen to cause the eruption.

12. Even if contrary to the facts presented in the record, an argument is made that LaBrea Williams had used and tolerated ibuprofen before, insufficient time had elapsed from her use on the afternoon of 6/1/02 to the early morning of 6/2/02 for even a previously sensitized individual to elicit the signs and symptoms described on 6/2/02. In fact, these 6/2/02 signs and symptoms represented the progression of LaBrea Williams's illness whose first signs and symptoms were manifest early on 6/1/02, well before she used ibuprofen.

13. Although TEN is most often a drug-induced illness, even in careful studies the attributable fraction (proportion due to drugs) is between 60 and 80% in adult populations. For EMM, SJS, and children with TEN, the proportion of cases attributable to drugs is even lower. Many of these cases are due to immunologic reactions to infectious illnesses such as virus. For LaBrea Williams, an immunologic reaction to an infectious illness or unknown environmental

exposure are the likely cause of her condition that began June 1, 2002. With an extremely high degree of medical certainty, ibuprofen can be excluded as the cause of her febrile mucocutaneous blistering eruption.

14. SJS and TEN are very rare conditions with about 2 to 5 cases occurring in a million persons in a year from all causes. The risk of SJS/TEN in association with ibuprofen is less than one in a million for persons that have used the drug for one week.

15. The overwhelming evidence is that there is a very low and comparable risk of SJS/TEN with acetaminophen and ibuprofen.


16. For example, in the international SJS/TEN Study, the risks of SJS/TEN associated with ibuprofen and acetaminophen are statistically the same. In fact, the point estimate for the risk of associated with acetaminophen is higher than that for ibuprofen (see Roujeau, et. al. *NEJM*, 1995 and Mockenhaupt, *J. Rheumatology*, 2003). I am an author of both of these papers and familiar with these results. I have spoken with Dr. Roujeau and confirmed that the additional data collected as part of the Euroscar study confirm that the risks of SJS/TEN associated with ibuprofen and acetaminophen are comparable and barely reach statistical significance.

17. The Plaintiff's experts place great emphasis on spontaneous reports indicating a high-risk of EM/SJS/TEN in association with ibuprofen use. First, the FDA Adverse Event Reporting System (AERS) is meant to be used for hypothesis generation and signaling of possible safety concerns with medications. Data from this system is not as robust as a well designed and executed case control study such as the international SCAR study which demonstrated comparable and low risks of EM/SJS/TEN in association with ibuprofen and acetaminophen use (see above). Secondly, a review of the AERS data from the fourth quarter of

1997 to the first quarter of 2004 indicates that ibuprofen was less than half as often reported as a suspect drug for EM/SJS/TEN as acetaminophen (78 reports with ibuprofen as a suspect drug for EM/SJS/TEN vs 200 reports for acetaminophen). Further, reports with ibuprofen, a very widely-used medicine, as a suspect drug for EM/SJS/TEN represent less than one half of one percent of the 16,271 drugs listed as "suspect" causes of EM/SJS/TEN, whereas acetaminophen reports comprised 1.2 percent of all drugs reported to AERS as suspect cause of EM/SJS/TEN. Third, because ibuprofen is often used to treat the first symptoms of EM/SJS/TEN (fever and malaise), as was the case in LaBrea Williams's illness, spontaneous reports are particularly subject to inappropriate causality assignment for ibuprofen, as the full signs and symptoms of an ongoing EM/SJS/TEN reaction, due to another cause, may not be manifest until after ibuprofen has been used to treat the first symptoms of EM/SJS/TEN.

18. In summary, there is no credible evidence that acetaminophen is less likely to cause EM/SJS/TEN than ibuprofen. Both of these medications are rare causes of these reactions

I declare under penalty of perjury that the foregoing is true and correct. Executed on April 18, 2005.



---

Robert S. Stern, M.D.

# **Exhibit 1**

**CURRICULUM VITAE**  
April 18, 2005

Name: Robert Stuart Stern

Address: 39 Clinton Road  
Brookline, MA 02445

Place of Birth: New Haven, Connecticut

Education:

1966 A.B. Harvard College (magna cum laude)  
1970 M.D. Yale University School of Medicine

Postdoctoral Training:

Internship and Residencies:

- 1970-1971 Intern in Internal Medicine, The Mount Sinai Hospital, New York, NY
- 1973-1976 Resident in Dermatology, Harvard Medical School, Massachusetts General Hospital, Boston, MA

Research Fellowships:

- 1971-1973 Research Associate, Clinical Epidemiology and Genetics, National Institute of Neurologic Diseases and Stroke, National Institutes of Health, Bethesda, MD
- 1974-1975 Research Fellow, Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
- 1975-1976 Fellow, Harvard Center for Community Health and Medical Care, Harvard Medical School, Boston, MA

Licensure and Certification:

- 1974 Massachusetts License Certificate No. 36176  
1977 American Board of Dermatology  
1987 Fellow, American College of Epidemiology

**Academic Appointments:**

1973-1976	Clinical Fellow in Dermatology, Harvard Medical School
1976-1979	Instructor in Dermatology, Harvard Medical School
1976-1983	Member, Center for the Analysis of Health Practice, Harvard School of Public Health
1979-1984	Assistant Professor of Dermatology, Harvard Medical School
1983-1990	Member, Institute for Health Research, Harvard School of Public Health
1984-1997	Associate Professor of Dermatology, Harvard Medical School
1997-2000	Professor of Dermatology, Harvard Medical School
2000-	Carl J. Herzog, Professor of Dermatology, Harvard Medical School

**Hospital Appointments:**

1976-1978	Associate in Dermatology, Beth Israel Hospital, Boston
1976-1978	Consultant in Dermatology, Boston Hospital for Women, Boston
1976-1980	Assistant in Dermatology, Children's Hospital Medical Center, Boston
1976-1979	Clinical Assistant in Dermatology, Massachusetts General Hospital, Boston
1977-	Consultant in Division of Medical Oncology, Sidney Farber Cancer Institute, Boston
1978-1982	Junior Associate in Medicine (Dermatology), Peter Bent Brigham Hospital, Boston
1978-1979	Assistant Dermatologist, Beth Israel Hospital, Boston
1979-1983	Associate Dermatologist, Beth Israel Hospital, Boston
1979-	Clinical Associate in Dermatology, Massachusetts General Hospital, Boston
1980-	Associate in Dermatology, Children's Hospital Medical Center, Boston
1982-	Associate Physician in Medicine (Dermatology), Brigham & Women's Hospital, Boston
1983-2000	Dermatologist, Beth Israel Hospital, Boston
1999-	Member, Harvard Cancer Center
1999-	Consultant, Children's Hospital Medical Center, Boston
2000-	Dermatologist-In-Chief, Beth Israel Deaconess Medical Center
2001-2003	Senior Consultant, Massachusetts General Hospital

**Other Professional Positions and Major Visiting Appointments:**

1971-1973	Senior Assistant Surgeon (1971-72), Surgeon (1972-73), U.S. Public Health Service, National Institutes of Health, Bethesda, MD
1971-1973	Consultant, Health Services Industries Committee, Cost of Living

	Council, Executive Office of the President
1976-1977	Research Fellowship Recipient, Dermatology Foundation
1979	Johns Hopkins Medical School
1984	New York University School of Medicine
1984-1992	Associate Editor, Archives of Dermatology
1985	University of Puerto Rico Medical School
1987	Johns Hopkins Medical School
1989	Dartmouth Medical School
1990-	Reviewer, Psoriasis: Professional Educational Materials: An Annotated Bibliography. National Institute of Musculoskeletal and Skin Diseases.
1990-	Reviewer, The World Book Encyclopedia, Chicago, IL: World Book Co., 1990.
1992-2000	Co-Editor, Archives of Dermatology
1993-2000	Editor, Medical and Surgical Dermatology: A Critical Guide To The Literature
1999-	Contributing Editor, Harvard Medical School Family Health Guide
2000-	Section Editor, Up to Date
2000-	Contributing Editor, Harvard Medical School/Intellihealth

#### Awards and Honors:

1966	Phi Beta Kappa, Harvard College
1966	Woodrow Wilson Scholar
1972	Letter of Commendation, The White House
1980	International Travel Award, French Society of Dermatology
1985	Milton Fund Fellowship

#### Major Committee Assignments:

##### National and Regional:

1981-1985	Advisory Panel on Dermatology, Member, U.S. Pharmacopeial Convention, Inc.
1983	Committee on Causes and Effects of Changes in Stratospheric Ozone: 1983 Update, Member, National Academy of Science
1983-1989	Project Advisory Committee and Safety and Data Monitoring Committee, Member, Beta Carotene as a Chemopreventive in Skin Cancer (National Institutes of Health funded multicenter study)
1984-1988	Dermatologic Drugs Advisory Committee, Member, U.S. Food and Drug Administration
1985	Committee to Evaluate Fansidar, Consultant, National Centers for Disease Control

1985-2000	General Committee of Revision, Member, U.S. Pharmacopeial Convention, Inc.
1985-2000	Advisory Panel on Dermatology, Chairman, U.S. Pharmacopeial Convention, Inc.
1986-1996	National Epidermolysis Bullosa Registry, Consultant
1988-1995	Executive Committee of Revision, Member, U.S. Pharmacopeial Convention, Inc.
1988-2003	Accutane Use Study, Slone Epidemiology Unit, Member, Advisory Committee, Boston University
1992-2000	Member, Steering Committee of the National EB Registry
1995-2000	Drug Information Executive Committee, Member, U.S. Pharmacopeial Convention, Inc.
1995-2002	National Skin Diseases Data Workgroup, Member, National Institutes of Health
1999-2000	U.S. Food and Drug Administration, Dermatologic and Ophthalmic Drug Advisory Committee
1999	Member, Institute of Medicine, Committee on Medicare Coverage Extensions
1999-	Member, Medical Advisory Board, National Psoriasis Foundation
1999-	Member, Board of Directors, The Photomedicine Society
2000	Ad Hoc Reviewer, National Institute of Arthritis Muscoskeletal and Skin Disease
2002-	
2001-2004	Chairman, US Food and Drug Administration, Dermatologic Drugs Advisory Committee
2005-	Consultant to US Food and Drug Administration

**Hospital:**

1974-1976	Representative for Dermatology, Massachusetts General Hospital House Officers Committee
1982-1987	Pharmacy and Therapeutics Committee, Beth Israel Hospital
1988-	Committee on Graduate Medical Education, Beth Israel Hospital
	Research Operations Committee, Beth Israel Hospital
2000-	Director, Residency Training in Dermatology, Beth Israel Hospital
	Chairman, Department of Dermatology, Beth Israel Deaconess Medical Center

**Departmental:**

1980-	Faculty Advisor
1983-1987	Resident Selection Committee
1984-	Executive Committee
1988-	Chairman, Clinical Research Committee

**Medical School:**

1993- Task Force on Ambulatory Education  
 1994- Committee on Ambulatory Education Self Assessment  
 1996-2000 Council for Research, Harvard Medical School - Beth Israel Deaconess Medical Center, Foundation for Research and Education  
 2003- Member, Subcommittee of Professors, Harvard Medical School  
 Memberships, Offices and Committee Assignments in Professional Societies:

1973- Society for Investigative Dermatology  
 1976- American Academy of Dermatology  
 1978-1981 Co-chairman, Committee on Therapeutics and Cosmetics, American Academy of Dermatology  
 1979- Dermatology Foundation  
 1979- New England Dermatologic Society  
 1979- Boston Dermatological Society  
 1980- American Society for Photobiology  
 1980-1986 Scientific Director, Adverse Drug Reaction Reporting System, American Academy of Dermatology  
 1980- American Society for Epidemiologic Research  
 1980-1983 Program Committee, Boston Dermatological Club  
 1981-1983 Chairman, Committee on Governmental Relations, American Academy of Dermatology  
 1981-1983 Council on Government Liaison, American Academy of Dermatology  
 1981-1988 American Society for Laser Medicine and Surgery  
 1981-1984 Committee on Regulatory Affairs, American Academy of Dermatology  
 1982-1985 Task Force on Psoriasis, American Academy of Dermatology  
 1983-1987 Member, American Academy of Epidemiology  
 1983-1986 Task Force on Dermatology/Pharmacy, American Academy of Dermatology  
 1983-1986 Task Force on Manpower, American Academy of Dermatology  
 1984- Council of Biology Editors  
 1984-1987 Committee on Diagnostic-Related Groups, American Academy of Dermatology  
 1985- Massachusetts Medical Society  
 1986-1989 Member, Committee on Psoriasis, American Academy of Dermatology  
 1986-1989 Chairman, Task Force on Relative Value Scales, American Academy of Dermatology  
 1986-1989 Chairman, Task Force on Dermatology/Pharmacy, American Academy of Dermatology  
 1986-1989 Committee on Psoriasis, American Academy of Dermatology  
 1986-1987 Chairman, Publications Committee, American Society for Laser Medicine and Surgery  
 1989-1993 Consultant, Seventh Edition, American Medical Association Drug

**Evaluations**

1989-1992 Member, Task Force on Federal Drug Administration Liaison, American Academy of Dermatology  
 1990-1992 Member, Task Force on Guidelines for Phototherapy, American Academy of Dermatology  
 1991-1993 Member, Task Force on Accutane, American Academy of Dermatology  
 1991- Member, American Dermatological Association  
 1991- Abstract Reviewer, Society of Investigative Dermatology  
 1994 Member, Scientific Committee, Congress on Cutaneous Drug Reactions, Paris  
 1995 Scientific Board, First International Conference on Epidemiology: Causes and Prevention of Skin Diseases, Marseille, France  
 1995 Scientific Program Committee, Photocarcinogenesis: Mechanisms, Models and Human Health Implications  
 1995-1997 Scientific Consultant, Multicenter Study (Italy) to assess efficacy of cimetidine in the treatment of psoriasis  
 1998 Scientific Committee, Second International Meeting on Epidemiology and Prevention of Skin Diseases  
 1998-2002 Steering Committee of the Cutaneous ADR-group  
 1999-2005 Medical Advisory Board, National Psoriasis Foundation  
 2000-2002 President, International Dermatoepidemiology Association  
 2001- Board Member, Photomedicine Society

**Editorial Boards:**

1982-1990 Section Editor, Year Book of Dermatology  
 1983- Archives of Dermatology (Associate Editor 1984-1992, Co-editor 1992 - present)  
 1988- Journal of Pharmacoepidemiology  
 1990-2000 Photodermatology, Photoimmunology, and Photomedicine  
 1993-2000 Section Editor, Clinical Pharmacology, Archives of Dermatology  
 1993-2000 Editor, Medical and Surgical Dermatology  
 1995-2000 International Editorial Board, Journal of Cutaneous Medicine and Surgery  
 2004- Photodermatology, Photoimmunology, and Photomedicine.

**Major Research Interests:**

1. Epidemiology of Dermatologic Disease
2. Psoriasis
3. Adverse Drug Reactions
4. Health Services Research
5. Photobiology

### Research Funding Information

<u>Past:</u>	1980-1986	USFDA, A specialty based adverse reaction PI reporting system (Scientific)	
	1983-1993	NIH, Phototherapy Follow-Up Study Assessment of risks and benefits of oral psoralen phototherapy for psoriasis	PI
	1986-1987	Milton Fund, Resource use by HMO and non-HMO patients	PI
	1988-1990	Massachusetts Fund for Cooperative Innovation, Co-PI Effects of socioeconomic status on cost of care and access to care.	
	1987-1992	Roche Laboratories, Etretinate Follow-Up Study Assessment of safety and efficacy of etretinate therapy for psoriasis, a multicenter 5-year 1,000 person cohort study.	PI
	1992-1994	Roche Laboratories, Epidemiology of Acne Database studies and cooperative population based study with the Mayo Clinic	PI
	1993-1995	USFDA, Ultraviolet Therapy Use Among HIV Infected Persons Assessment of ultraviolet radiation in the treatment of cutaneous disease in HIV-infected persons	
	1996-1998	NIH, RO1 CA76174 - O1A1 Genetic alterations in PUVA induced skin cancers	Co-PI
	1999-2005	NIH, Follow-Up Study of Patients Treated with Oral Psoralen Phototherapy Assessment of long-term risk of oral psoralen phototherapy	PI
	2000-2001	Searle, Epidemiologic Assessment of Risk of SJS and TEN in association with NSAIDs	

**Principal Clinical and Hospital Service Responsibilities:**

- 1976- Attending Physician, Dermatology Clinic, Beth Israel Hospital, once weekly
- 1976- Attending Physician, Consultation Service, Beth Israel Hospital, three times per month
- 1978- Director, Phototherapy Center, Beth Israel Hospital
- 2000- Dermatologist-In-Chief, Beth Israel Deaconess Medical Center

**Self Report of Teaching:****Local Contributions:****Harvard Medical School Undergraduate Courses:**

- 1976- Preceptor, Dermatology Clinical Clerkship, Multiple Months each year
- 1977-1985 Section Leader, Pathophysiology of the Skin
- 1985-2000 Lecturer, Pathophysiology of the Skin (most years)
- 1985- Supervisor, Medical student research projects (1-2 Harvard Medical School students/yearly)
- 1991-1993 Preceptor for Dermatology, Introduction to Clinical Medicine
- 1991- Preceptor, Ambulatory Care Clerkships
- 2000- Senior Institute Scholar, The Carl J. Shapiro Institute for Education and Research at Harvard Medical School

**Department of Dermatology, Harvard Medical School:**

- 1976- Dermatology Literature Review, Dermatology Residency Training Program (1-2 times/monthly)
- 1976- Combined Longwood Avenue Area Dermatology Grand Rounds (1-2 months/yearly)
- 1976- Dermatology Grand Rounds, Massachusetts General Hospital (1-3 times/yearly)
- 1976- Faculty Advisor, Dermatology Residency Training Program (1 resident per year)
- 1980- Clinical Fellowship Program, Beth Israel Hospital (0-2 fellows/yearly)
- 1990 Lecturer, Collaborative Course on Biology of the Skin, Boston, MA

**Beth Israel Hospital Lectures and Rounds:**

1976 -           Lecturer, Medical Grand Rounds  
                     Presentations to Beth Israel Hospital Departments of Medicine  
                     and Surgery including Rounds from conferences, lecture series,  
                     Emergency Ward Conferences

**Harvard Medical School Postgraduate Courses:**

1978-1982	Faculty, Adolescent Medicine Course Management of Medical and Surgical Emergencies
1979-1981	Faculty, Argon Laser and Cutaneous Vascular Surgery
1983	Co-Director, Cutaneous Laser Therapy
1985	Co-Director, Cutaneous Laser Therapy
1989	Faculty, Update in Cutaneous Laser Surgery
1994	Lecturer, Update in Internal Medicine
1995	Lecturer, Dermatology for the Practicing Physician

**Harvard College:**

1976-1979	Premedical Advisor, Kirkland House, Harvard College
1983	Lecturer, Harvard College Biology Seminar

**Harvard School of Public Health:**

1976-2000	Lecturer, Courses, symposia, workshops on health services research and occupational dermatology
1977-1997	Postgraduate Courses in Occupational Medicine
1977-1980	Participant, Faculty Seminar on Health Care Technology, Harvard School of Public Health
1979-1989	Consultant for Health Hazard Evaluations, Harvard School of Public Health, Occupational Health Program
1980	Lecturer, Seminar on Decision Analysis
1986	Faculty, Postgraduate Course on Medical Decision-Making

**Other Local Hospitals and Medical Schools:**

1976-	Medical Grand Rounds, Cambridge Hospital
1976-	Medical Grand Rounds, Veterans Administration Hospital
1976-	Dermatology Grand Rounds, Tufts University/Boston University Schools of Medicine

1977	Lecturer, Winchester Hospital
1977	Lecturer, Cooley-Dickenson Hospital (Northhampton, MA)
1977	Lecturer, Cable Memorial Hospital (Ipswich, MA)
1977	Lecturer, Noble Hospital (Westfield, MA)
1977	Lecturer, Hale Hospital (Haverhill, MA)
1977	Lecturer, Harrington Memorial Hospital (Southbridge, MA)
1981	Resident Education Lecture Series, Memorial Hospital, University of Massachusetts Medical School, Worcester
1982-	Lecturer, Postgraduate Course on Industrial Medicine, Boston University School of Nursing
1995-	Lecturer, Core Curriculum in Primary Care, Boston

**Regional, National, and International Contributions:**

1976	Dermatology Grand Rounds, Johns Hopkins Medical Institute
1977	Lecturer, UCLA School of Medicine
1978-	American Academy of Dermatology Annual Meetings (or talk(s) at each meeting related to psoriasis, epidemiology, and drug reactions)
1978	Society of Investigative Dermatology Annual Meeting, Participation in workshops and presentation of scientific papers
1979	Lecturer, Course on Empiric Risk of Genetic Disease, American Public Health Association, Annual Meeting
1979	Consultant to Dermatology Advisory Panel, Food and Drug Administration (multiple meetings)
1980	Invited Presentation and Travel Fellowship, VIII International Photobiology Conference, Strasbourg, France
1981	Lecturer, International Symposium on Psoralens and the Skin, Paris, France
1981	Faculty, Third International Symposium on Psoriasis, Stanford University
1981	Invited Lecturer, Workshop on Biological Effects of Increased Solar Ultraviolet Radiation, National Academy of Sciences Meeting
1982	Guest Faculty, Johns Hopkins Medical Institution Course on Phototherapy
1982	Lecturer, Conference on Photobiology, Toxicologic and Pharmacologic Aspects of Psoralens, National Institutes of Environmental Health and Safety, Research Triangle, North Carolina
1983	Lecturer, Grand Rounds, University of Pennsylvania, Department of Dermatology
1984	George Fox Lecturer, New York University School of Medicine, Department of Dermatology

1984	Lecturer, Swedish Dermatologic Association, Annual Clinical Meeting, Uppsala, Sweden
1984	Lecturer, George Washington University, Drug Induced Diseases Symposium, Bethesda, MD
1985	Visiting Professor, University of Puerto Rico School of Medicine
1985	Lecturer, Second World Congress on Cancers of the Skin, New York
1985	Lecturer, Johns Hopkins School of Medicine
1985	Faculty, First International Dermatopharmacology Symposium, Vancouver, B.C., Canada
1985	Faculty, Uniformed Services University of the Health Sciences Continuing Medical Education Dermatology Conference, Mannheim, Germany
1986	Speaker, Drug Information Association Symposium: The Future of Adverse Drug Reaction Diagnosis, Arlington, VA
1986	Faculty, Second International Dermatopharmacology Symposium, Vancouver, B.C., Canada
1986	Co-chair, Phototherapy Symposium, Fourth International Symposium on Psoriasis, Stanford, CA
1986	Faculty, Anglo-Nordic Symposium on the Long Term Care of Psoriasis, Helsinki, Finland
1987	Faculty, Third International Dermatopharmacology Symposium, Vancouver, B.C.
1988	Faculty, International Symposium on Psoralens, Paris
1988	Faculty, Drug Information Association, Workshop on Cost-Benefit Analysis of Pharmaceutical Products, Hilton Head, SC
1988	Speaker, Dermatology Nurses Association, Annual Meeting, Washington, DC
1989	Speaker, National Institutes of Health Consensus Development Conference on Sunlight, Ultraviolet Radiation and Health, Bethesda, MD
1989	Lecturer, New Jersey Dermatologic Society
1989	Faculty, Fourteenth Congress of the European Academy of Allergology and Clinical Immunology, Berlin, W. Germany
1989	Speaker, Fifth Annual International Pharmacoepidemiology Conference, Minneapolis, MN
1989	Faculty, Dermatology 89: Therapeutic Update, Vancouver, B.C., Canada
1990	Lecturer, Noncognoscenti Session: Epidemiology and Clinical Research, Society of Investigative Dermatology, Annual Meeting, Washington, DC
1990	Speaker, Atlantic Dermatology Conference, Boston, MA

- 1991                    National Institute of Arthritis and Musculoskeletal and Skin Disease, National Research Plan Task Force Meeting, Maryland
- 1991                    Lecturer, Eighth Advanced Course in Dermatology, Institute of Dermatology, Brighton, England
- 1991                    Lecturer, Skin Disease Research Center, Case-Western Reserve University, Cleveland, OH
- 1991                    Invited Lecturer, Annual Meeting, American Society for Photobiology, San Antonio, TX, June 1991
- 1991                    Faculty, Fifth International Psoriasis Symposium, San Francisco, CA, July 1991
- 1991                    Faculty, Institute of Dermatology's Annual Course for Consultants and Senior Registrars, Brighton, England, February 1991
- 1992                    Director, Forum on Epidemiology and Biostatistics, Annual Meeting, American Academy of Dermatology, San Francisco, CA
- 1992                    Faculty, National Conference on Environmental Hazards to the Skin, Washington, D.C.
- 1992                    Lecturer, 69th Atlantic Dermatological Conference, Washington, D.C.
- 1992                    Faculty, International Dermatopharmacology Symposium, Brussels, Belgium
- 1993                    Planning Committee and Faculty, Scientific Workshop Epidemiology of Skin Diseases, National Institute of Health, Bethesda, MD, March 1993
- 1993                    Lecturer, 26th Nordic Dermatologic Conference, Reykjavik, Iceland, June 1993
- 1993                    Faculty, American Academy of Dermatology, Washington, D.C., December 1993
- 1994                    Faculty, First International Symposium on Severe Adverse Cutaneous Reactions to Drugs, Paris, September 1994
- 1994                    Visiting Professor, University of West Virginia School of Medicine
- 1995                    Lecturer, International Conference on Epidemiology of Skin Disease, Marseille, France
- 1995                    Invited Lecturer, American Society of Photobiology, Annual Meeting, Washington, D.C.
- 1995                    Faculty, American Academy of Dermatology, Annual Meeting, New Orleans
- 1995                    Samuel Peck Lecturer, Mt. Sinai Medical Center, NY, NY
- 1995                    Faculty, Johns Hopkins University Postgraduate Medical Education Course, Baltimore
- 1996                    Lecturer, Irish Association of Dermatologists, Spring Meeting, Cavan, Ireland
- 1996                    Invited Lecturer, Photomedicine Society Annual Meeting,

Washington, D.C.  
 1996 Faculty, American Academy of Dermatology, Annual Meeting, Washington D.C.  
 1996 Invited Lecturer, French Dermatologic Association, Paris  
 1996 Faculty, Symposium on "Toxidermies", Societe Medicale des Hopitaux de Paris, Paris, France  
 1996 Scientific Committee and Faculty, Congress on Cutaneous Drug Reactions, Rome, Italy  
 1996 Invited Lecturer, Dermatology 2000, Vancouver, British Columbia  
 1996 Invited Speaker, Workshop on Patient Outcomes in Basal Cell and Squamous Cell Skin Cancer, National Institute of Health, Bethesda, MD  
 1997 Invited Speaker, Skin Disease Symposium, Israel  
 1998 Invited Speaker, USFDA, Dermatology Advisory Committee, Evaluation of Psoriasis, Gaithersburg, Maryland  
 1998 Invited Speaker, International Congress of Toxicology, Paris, France  
 1998 Invited Speaker, Research Workshop on Risks and Benefits of Exposure to Ultraviolet Radiation and Tanning, National Institute of Health  
 1998 Invited Speaker, Toxicology Forum, Given Institute, Aspen, Colorado  
 1999 Visiting Professor, Universities of Marsielles, Bourdeaux, and Rouen, France  
 2001 Speaker, Seminars in Clinical and Molecular Oncology, National Institute of Health, Bethesda, MD  
 2002 Visiting Professor, University of Connecticut, School of Medicine  
 2002 Speaker, USFDA Seminars, Drug Eruptions in Clinical Trials  
 2002 Invited Speaker, World Congress of Dermatology, Paris, France  
 2002 Invited Speaker Workshops on Burden of Skin Disease, National Institute of Health, Bethesda, MD  
 2003 Invited Speaker, European Academy of Dermatovenerology, Barcelona, Spain  
 2004 Invited Speaker, Eden Symposium How to Perform Clinical Trials for Psoriasis, University of Geneva, Geneva, Switzerland  
 2005 Invited Speaker, EDEN-IDEA Congress, Venice, Italy 2004

## BIBLIOGRAPHY

### Original Contributions

1. Wooten GF, Eldridge R, Axelrod J, Stern RS. Elevated plasma dopamine beta hydroxylase activity in autosomal dominant torsion dystonia. *N Engl J Med* 1973; 288:284-7.
2. Koch MJ, Reed D, Stern RS, Brody JA. Multiple sclerosis. A cluster in a small Northwestern United States community. *JAMA* 1974; 228:1555-7.
3. Stern RS, Eldridge R. Attitudes of patients and their relatives to Huntington's disease. *J Med Genet* 1975; 12:217-23.
4. Stern RS, Johnson ML, DeLozier J. Utilization of physician services for dermatologic complaints. The United States, 1974. *Arch Dermatol* 1977; 113:1062-6.
5. Stern RS, Jennings M, Delbanco TL, Dorsey JL, Stoeckle JD, Lawrence RS. Graduate education in primary care: an economic analysis. *N Engl J Med* 1977; 297:638-43.
6. Stern RS, Thibodeau LA, Kleinerman RA, Parrish JA, Fitzpatrick TB. Risk of cutaneous carcinoma in patients treated with oral methoxsalen photochemotherapy for psoriasis. *N Engl J Med* 1979; 300:809-13.
7. Stern RS, Morison WL, Thibodeau LA, Kleinerman RA, Parrish JA, Geer DE, Fitzpatrick TB. Antinuclear antibodies and oral methoxsalen photochemotherapy (PUVA) for psoriasis. *Arch Dermatol* 1979; 115:1320-4.
8. Stern RS, Calkins D, Lawrence R, Delbanco T. Joining a rural practice: a pilot program in primary care education in internal medicine. *J Ambul Care Manage* 1980; 1:89-95.
9. Stern RS, Zierler S, Parrish JA. Skin carcinoma in patients with psoriasis treated with topical tar and artificial ultraviolet radiation. *Lancet* 1980; 1:732-5.
10. Stern RS, Kleinerman RA, Parrish JA, Fitzpatrick TB, Bleich HL. Phototoxic reactions to photoactive drugs in patients treated with PUVA. *Arch Dermatol* 1980; 116:1269-71.

11. Stern RS, Thibodeau LA, Kleinerman RA, Parrish JA, Fitzpatrick TB, Bleich HL. Effect of oral methoxsalen photochemotherapy on cost of treatment for psoriasis. An example of technological assessment. *JAMA* 1981; 245:1913-8.
12. Melski JW, Stern RS. The separation of susceptibility to psoriasis from age at onset. *J Invest Dermatol* 1981; 77:474-7.
13. Gilchrest BA, Stern RS, Steinman TI, Brown RS, Arndt KA, Anderson WW. Clinical features of pruritus among patients undergoing maintenance hemodialysis. *Arch Dermatol* 1982; 118:154-6.
14. Stern RS, Zierler S, Parrish JA. Psoriasis and the risk of cancer. *J Invest Dermatol* 1982; 78:147-9.
15. Melski JW, Stern RS. Annual rate of psoralen and ultraviolet-A treatment of psoriasis after initial clearing. *Arch Dermatol* 1982; 118:404-8.
16. Stern RS, Melski JW. Long-term continuation of psoralen and ultraviolet-A treatment of psoriasis. *Arch Dermatol* 1982; 118:400-3.
17. Stern RS, Zierler S, Parrish JA. Methotrexate used for psoriasis and the risk of noncutaneous or cutaneous malignancy. *Cancer* 1982; 50:869-72.
18. Morison WL, Stern RS. Polymorphous light eruption: a common reaction uncommonly recognized. *Acta Derm Venereol (Stockh)* 1982; 62:237-40.
19. Paul BS, Momtaz K, Stern RS, Arndt KA, Parrish JA. Combined methotrexate--ultraviolet B therapy in the treatment of psoriasis. *J Am Acad Dermatol* 1982; 7:758-62.
20. Arndt KA, Paul BS, Stern RS, Parrish JA. Treatment of pityriasis rosea with UV radiation. *Arch Dermatol* 1983; 119:381-2.
21. Paul BS, Stern RS, Parrish JA, Arndt KA. Low intensity selective UV phototherapy. A clinical trial in outpatient therapy for psoriasis. *Arch Dermatol* 1983; 119:122-4.
22. Melski JW, Bernhard JD, Stern RS. The Koebner (isomorphic) response in psoriasis. Associations with earlier age at onset and multiple previous therapies. *Arch Dermatol* 1983; 119:655-9.
23. Read JL, Stern RS, Thibodeau LA, Geer DE, Klapholz H. Variation in antenatal testing over time and between clinic settings. *JAMA* 1983; 249:1605-9.

24. Rhodes AR, Stern RS, Melski JW. The PUVA lentigo: an analysis of predisposing factors. *J Invest Dermatol* 1983; 81:459-63.
25. Eldridge R, Iivanainen M, Stern RS, Koerber T, Wilder BJ. "Baltic" myoclonus epilepsy: hereditary disorder of childhood made worse by phenytoin. *Lancet* 1983; 2:838-42.
26. Diette KM, Gange RW, Stern RS, Arndt KA, Parrish JA. Coal tar phototoxicity: kinetics and exposure parameters. *J Invest Dermatol* 1983; 81:347-50.
27. Stern RS, Momtaz-T K. Skin typing for assessment of skin cancer risk and acute response to UV-B and oral methoxsalen photochemotherapy. *Arch Dermatol* 1984; 120:869-73.
28. Stern RS, Pass TM, Komaroff AL. Topical versus systemic agent treatment for papulopustular acne. A cost-effectiveness analysis. *Arch Dermatol* 1984; 120:1571-8.
29. Diette KM, Momtaz-T K, Stern RS, Arndt KA, Parrish JA. The role of ultraviolet A in phototherapy for psoriasis. *J Am Acad Dermatol* 1984; 11:441-7.
30. Diette KM, Momtaz-T K, Stern RS, Arndt KA, Parrish JA. Psoralens and UV-A and UV-B twice weekly for the treatment of psoriasis. *Arch Dermatol* 1984; 120:1169-73.
31. Stern RS, Rosa F, Baum C. Isotretinoin and pregnancy. *J Am Acad Dermatol* 1984; 10:851-4.
32. Stern RS, Laird N, Melski J, Parrish JA, Fitzpatrick TB, Bleich HL. Cutaneous squamous-cell carcinoma in patients treated with PUVA. *N Engl J Med* 1984; 310:1156-61.
33. Stern RS, Bigby M. An expanded profile of cutaneous reactions to nonsteroidal anti-inflammatory drugs. Reports to a specialty-based system for spontaneous reporting of adverse reactions to drugs. *JAMA* 1984; 252:1433-7.
34. Kopf AW, Kripke ML, Stern RS. Sun and malignant melanoma. *J Am Acad Dermatol* 1984; 11:674-84..
35. Stern RS, Parrish JA, Fitzpatrick TB, Bleich HL. Actinic degeneration in association with long-term use of PUVA. *J Invest Dermatol* 1985; 84:135-8.
36. Stern RS, Dodson TB. Ibuprofen in the treatment of UV-B-induced inflammation. *Arch Dermatol* 1985; 121:508-12.

37. Menkes A, Stern RS, Arndt, KA. Psoriasis treatment with suberythemogenic ultraviolet B radiation and a coal tar extract. *J Am Acad Dermatol* 1985; 12:21-5.
38. Stern RS. The epidemiology of joint complaints in patients with psoriasis. *J Rheumatol* 1985; 12:315-20.
39. Stern RS, Scotto J, Fears T. Psoriasis and susceptibility to nonmelanoma skin cancer. *J Am Acad Dermatol* 1985; 12:67-73
40. Stern RS, Epstein AM. Institutional responses to prospective payment based on diagnosis-related groups. Implications for cost, quality and access. *N Engl J Med* 1985; 312:621-7.
41. Kamat BR, Tang SV, Arndt KA, Stern RS, Noe JM, Rosen S. Low-fluence CO<sub>2</sub> irradiation: selective epidermal damage to human skin. *J Invest Dermatol* 1985; 85:274-8.
42. Stern RS, Parrish JA, Fitzpatrick TB. Ocular findings in patients treated with PUVA. *J Invest Dermatol* 1985; 85:269-73.
43. Bigby M, Stern RS, Bigby JA. An evaluation of method reporting and use in clinical trials in dermatology. *Arch Dermatol* 1985; 121:1394-9.
44. Diette KM, Gange RW, Stern RS, Arndt KA, Parrish JA. Coal tar phototoxicity: Characteristics of the smarting reaction. *J Invest Dermatol* 1985; 84:268-71.
45. Stern RS, and the members of the 16-center PUVA Follow-up Study. Long-term use of psoralens and ultraviolet A for psoriasis: evidence for efficacy and cost savings. *J Am Acad Dermatol* 1986; 14:520-6.
46. Stern RS, Gardocki GJ. Office-based care of dermatologic disease. *J Am Acad Dermatol* 1986; 14:286-93.
47. Kamat BR, Carney JM, Arndt KA, Stern RS, Rosen S. Cutaneous tissue repair following CO<sub>2</sub> laser irradiation. *J Invest Dermatol* 1986; 87:268-71.
48. Stern RS, Gange RW, Parrish JA, Tang SV, Arndt KA. Contribution of topical tar oil to ultraviolet B phototherapy for psoriasis. *J Am Acad Dermatol* 1986; 14:742-7.
49. Stern RS, Armstrong RB, Anderson TF, Bickers DR, Lowe NJ, Harber L, Voorhees J, Parrish JA. Effect of continued ultraviolet B phototherapy on the duration of remission of psoriasis: a randomized study. *J Am Acad Dermatol* 1986; 15:546-52.

50. Miller KD, Lobel HO, Satriale RF, Kuritsky JN, Stern R, Campbell CC. Severe cutaneous reactions among American travelers using Pyrimethamine - Sulfadoxine (Fansidar - R) for malaria prophylaxis. *Am J Trop Med Hyg* 1986; 35:451-8.
51. Stern RS, Weinstein MC, Baker SG. Risk reduction for nonmelanoma skin cancer with childhood sunscreen use. *Arch Dermatol* 1986; 122:537-45.
52. Stern RS. Topical minoxidil. A survey of use and complications. *Arch Dermatol* 1987; 123:62-5.
53. Olbricht SM, Stern RS, Tang SV, Noe JM, Arndt KA. Complications of cutaneous laser surgery. A survey. *Arch Dermatol* 1987; 123:345-9.
54. Rosen CF, Seki Y, Farinelli W, Stern RS, Fitzpatrick TB, Pathak MA, Gange RW. A comparison of the melanocyte response to narrow band UVA and UVB exposure in vivo. *J Invest Dermatol* 1987; 88:774-9.
55. Rhodes AR, Seki Y, Fitzpatrick TB, Stern RS. Melanosomal alterations in dysplastic melanocytic nevi. A quantitative, ultrastructural investigation. *Cancer* 1988; 61:358-69.
56. Bigby M, Stern RS. Adverse reactions to isotretinoin. A report from the Adverse Drug Reporting System. *J Am Acad Derm* 1988; 18:543-52.
57. Epstein AM, Stern RS, Tognetti J, Begg CB, Hartley RM, Cumella E, Ayanian JZ. The association of patients' socioeconomic characteristics with the length of hospital stay and hospital charges within diagnosis-related groups. *N Engl J Med* 1988; 318:1579-85.
58. Gupta AK, Stern RS, Swanson NA, Anderson TF. Cutaneous melanomas in patients treated with psoralens plus ultraviolet-A. A case report and the experience of the PUVA Follow-up Study. *J Am Acad Dermatol* 1988; 19:67-76.
59. Dover JS, Smoller BR, Stern RS, Rosen S, Arndt KA. Low-fluence carbon dioxide laser irradiation of lentigines. *Arch Dermatol* 1988; 124:1219-24.
60. Stern RS, Lange R. Non-melanoma skin cancer occurring in patients treated with PUVA five to ten years after first treatment. *J Invest Dermatol* 1988; 91:120-4.
61. Stern RS, Lange R. Cardiovascular disease, cancer, and cause of death in patients with psoriasis: 10 years prospective experience in a cohort of 1,380 patients. *J Invest Dermatol* 1988; 91:197-201.

62. Stern RS. Childhood sunscreen use: Factors affecting cost effectiveness. *Drug Info J* 1988; 22:471-5.
63. Stern RS. The benefits, costs, and risks of topical tar preparations in the treatment of psoriasis: considerations of cost-effectiveness. *Ann Acad Med Singapore* 1988; 17:473-6.
64. Stern RS, Khalsa JH. Cutaneous adverse reactions associated with calcium channel blockers. *Arch Intern Med* 1989; 149:829-32.
65. Stern RS. When a uniquely effective drug is teratogenic. The case of isotretinoin. *N Engl J Med* 1989; 320:1007-9.
66. Dover JS, McEvoy MT, Rosen CF, Arndt KA, Stern RS. Are topical corticosteroids useful in phototherapy for psoriasis? *J Am Acad Dermatol* 1989; 20:748-54.
67. Stern RS, Juhn PI, Gertler PJ, Epstein AM. A comparison of length of stay and costs for health maintenance organizations and fee-for-service patients. *Arch Intern Med* 1989; 149:1185-8.
68. Stern RS, Chan HL. Usefulness of case report literature in determining drugs responsible for toxic epidermal necrolysis. *J Am Acad Dermatol* 1989; 21:317-22.
69. Chan HL, Stern RS, Arndt KA, Langlois J, Jick SS, Jick H, Walker AM. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients. *Arch Dermatol* 1990; 126:43-7.
70. Lindelöf B, Eklund G, Liden S, Stern RS. The prevalence of malignant tumors in patients with psoriasis. *J Am Acad Dermatol* 1990; 22:1056-60.
71. Epstein AM, Stern RS, Weissman JS. Do the poor cost more? A multihospital study of patients' socioeconomic status and use of hospital resources. *N Engl J Med* 1990; 322:1122-8.
72. Stern RS and members of the Photocemoetherapy Follow-up Study. Genital tumors among men with psoriasis exposed to psoralens and ultraviolet-A radiation (PUVA) and ultraviolet-B radiation. The photocemoetherapy follow-up study. *N Engl J Med* 1990; 322: 1093-7.
73. Strom BL, Carson JL, Halpern AA, Schinnar R, Snyder ES, Stolley PD, Shaw M, Tilson HH, Joseph M, Dai WS, Chen D, Stern RS, Berman U, Lundin F. Using a

- claims database to investigate drug induced Stevens-Johnson Syndrome. Stat Med 1991; 10:565-76.
74. Stern RS, Lange R, and members of the Photochemotherapy Follow-up Study. Outcomes of pregnancies among women and partners of men with a history of exposure to methoxsalen photochemotherapy (PUVA) for the treatment of psoriasis. Arch Dermatol 1991; 127:347-50.
  75. Stern RS, Boudreaux C, Arndt KA. Diagnostic accuracy and appropriateness of care for seborrheic keratoses. A pilot study of an approach to quality assurance for cutaneous surgery. JAMA 1991; 265:74-7.
  76. Strom BL, Carson JL, Halpern AC, Schinnar R, Snyder ES, Shaw M, Tilson HH, Joseph M, Dai WS, Chen D, Stern RS, et al. A population-based study of Stevens-Johnson syndrome: Incidence and antecedent drug exposures. Arch Dermatol 1991; 127:831-8.
  77. Weissman JS, Stern RS, Fielding SL, Epstein AM. Delayed access to health care: risk factors, reasons, and consequences. Ann Intern Med 1991; 114:325-31.
  78. Taylor CR, Stern RS. Magnitude and duration of UV-B induced tolerance. Arch Dermatol 1991; 127:673-7.
  79. Stern, RS, Weissman JS, Epstein AM. The emergency department as a pathway to admission for poor and high-cost patients. JAMA 1991; 266:2238-43.
  80. Stern RS. The prevalence of acne on the basis of physical examination. J Am Acad Dermatol 1992; 26:931-5.
  81. Dai WS, LaBraico JM, Stern RS. Epidemiology of isotretinoin exposure during pregnancy. J Am Acad Dermatol 1992; 26:599-606.
  82. Karagas MR, Stukel TA, Greenberg ER, Baron JA, Mott LA, Stern RS. Risk of subsequent basal cell carcinoma and squamous cell carcinoma of the skin among patients with prior skin cancer. Skin Cancer Prevention Study Group. JAMA 1992; 267:3305-10.
  83. Caldwell-Brown D, Stern RS, Lin AN, Carter DM. Lack of efficacy of phenytoin in recessive dystrophic epidermolysis bullosa. Epidermolysis Bullosa Study Group. N Engl J Med 1992; 327:163-7
  84. Stern RS, Albengres E, Carlson J, Chen D, Dai W, Joseph M, Tilson H, Wiholm BE, Kraft C. An international comparison of case definition of severe adverse

- cutaneous reactions to medicines. *Drug Saf* 1993; 8:67-77.
85. Bastaj-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. A clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson Syndrome, and erythema multiforme. *Arch Dermatol* 1993; 129:92-6.
  86. DeCoste S, Stern RS. The diagnosis and treatment of nevomelanocytic lesions of the skin: A community-based study. *Arch Dermatol* 1993; 129:57-62.
  87. Coopman SA, Johnson RA, Platt R, Stern RS. Cutaneous disease and drug reactions in HIV infection: A population based study. *N Engl J Med* 1993; 328:1670-4.
  88. Stern RS, Nelson C. The diminishing role of the dermatologist in office-based care of cutaneous diseases. *J Am Acad Dermatol* 1993; 29:773-7.
  89. Weissman JS, Stern RS, Epstein AM. The impact of patient socioeconomic status and other social factors on readmission. A prospective study in four Massachusetts hospitals. *Inquiry* 1994; 31:163-72.
  90. Stern RS, Dover JS, Levin JA, Arndt, KA. Laser therapy versus cryotherapy of lentigines: A comparative Trial. *J Am Acad Dermatol* 1994; 30:985-7.
  91. Stern RS, Laird N. The carcinogenic risk of treatments for severe psoriasis. Photochemotherapy follow-up study. *Cancer* 1994; 73:2759-64.
  92. Stern RS and members of the Photochemotherapy Follow-up Study. Ocular lens findings in patients treated with PUVA. *J Invest Dermatol* 1994; 103:534-8.
  93. Lowe NJ, Fakouhi TD, Stern RS, Bourget BS, Roniker B, Swabb EA. Photoreactions with a fluoroquinolone: evening versus morning dosing. *Clin Pharmacol Ther* 1994; 56:587-91.
  94. Stern RS. Drug promotion for an unlabeled indication: The case of topical tretinoin. *N Engl J Med* 1994; 331:1348-9.
  95. Dover JS, Geronemus R, Stern RS, O'Hare D, Arndt KA. Dye laser treatment of port-wine stains: comparison of the continuous-wave dye laser with a robotized scanning device and the pulsed dye laser. *J Am Acad Dermatol* 1995; 32:237-40.
  96. Stern RS, Fitzgerald E, Ellis CN, Lowe N, Goldfarb M, Baughman RD. The safety of etretinate in long-term use for psoriasis: Results of the etretinate follow-up study. *J Am Acad Dermatol* 1995; 33:44-52.
  97. McKenna K, Stern RS. Photosensitivity associated with combined UVB and